# EDGAR Filing Document

**Accession Number:** 0000790526
**File Stem:** 0001683168-25-008894
**Filing Date:** 2025-12
**Character Count:** 171472
**Document Hash:** b20803316fc88e69d0c754d396b1cafe
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-25-008894.hdr.sgml**: 20251204

**ACCESSION NUMBER**: 0001683168-25-008894

**CONFORMED SUBMISSION TYPE**: S-3ASR

**PUBLIC DOCUMENT COUNT**: 17

**FILED AS OF DATE**: 20251204

**DATE AS OF CHANGE**: 20251204

**EFFECTIVENESS DATE**: 20251204

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RadNet, Inc.
- **CENTRAL INDEX KEY:** 0000790526
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 133326724
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-3ASR
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291945
- **FILM NUMBER:** 251550494

**BUSINESS ADDRESS:**
- **STREET 1:** 1510 COTNER AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90025
- **BUSINESS PHONE:** 3104787808

**MAIL ADDRESS:**
- **STREET 1:** 1510 COTNER AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90025

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRIMEDEX HEALTH SYSTEMS INC
- **DATE OF NAME CHANGE:** 19930518

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CCC FRANCHISING CORP
- **DATE OF NAME CHANGE:** 19920703

[**Table of Contents**](#s3_02)

Registration No. 333-

**As filed with the Securities and Exchange Commission on December 4, 2025**

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**<br> __________________________

**FORM S-3<br> REGISTRATION STATEMENT UNDER<br> THE SECURITIES ACT OF 1933**<br> __________________________

**RADNET, INC.** ****<br> (Exact Name of Registrant as Specified in Its Charter)

---

| | |
|:---|:---|
| **Delaware** | **13-3326724** |
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification Number) |

---

**1510 Cotner Avenue<br> Los Angeles, California, 90025<br> (310) 478-7808**<br> (Address, Including Zip Code, and Telephone Number, Including<br> Area Code, of Registrant's Principal Executive Offices)

__________________________

Howard G. Berger, M.D.<br> President and Chief Executive Officer<br> RadNet, Inc.<br> 1510 Cotner Avenue<br> Los Angeles, California 90025<br> (310) 478-7808<br> (Name, Address, Including Zip Code, and Telephone Number,<br> Including Area Code, of Agent for Service)

__________________________

 ****

***Copies To:***

**Anne G. Peetz**

**Lynwood E. Reinhardt<br> Reed Smith LLP**

**2850 N. Harwood Street, Suite 1500**

**Dallas, TX 75201**

**Telephone: (469) 680-4220**

__________________________

**Approximate date of commencement of proposed sale to the public:<br> From time to time after this registration statement becomes effective.**

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☒

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ <br> Non-accelerated filer ☐ Smaller reporting company ☐ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**PROSPECTUS**

**COMMON STOCK<br> PREFERRED STOCK<br> DEBT SECURITIES<br> WARRANTS<br> SUBSCRIPTION RIGHTS<br> UNITS**

**and**

**Common Stock<br> Offered by Selling Stockholders**

__________________________

From time to time, we may offer and sell the securities described in this prospectus separately or together in any combination, in one or more classes or series, in amounts, at prices and on terms that we will determine at the time of the offering. In addition, selling stockholders may offer and sell from time to time shares of our common stock.

This prospectus provides you with a general description of the securities we may offer. Each time we offer securities pursuant to this prospectus, we will provide a prospectus supplement containing specific terms of the particular offering together with this prospectus. You should carefully read this prospectus, the information incorporated by reference in this prospectus, the prospectus supplement, including any information incorporated by reference in such prospectus supplement, and any free writing prospectus before you purchase any of the securities offered hereby. The prospectus supplement also may add, update or change information contained in this prospectus. This prospectus may not be used to offer and sell securities unless accompanied by the applicable prospectus supplement.

We or selling stockholders may sell the securities offered by this prospectus directly to purchasers, or to or through underwriters or dealers or agents. In addition, the underwriters, if any, may over-allot a portion of the securities. The names of any underwriters, dealers or agents involved in the sale of securities offered by this prospectus, their compensation and any options held by them to purchase additional securities will be described in the applicable prospectus supplement. See "[Plan of Distribution.](#s3_18)" We will not receive any proceeds from the sale of common stock by selling stockholders.

Our common stock is listed on the NASDAQ Global Market under the symbol "RDNT." On December 3, 2025, the closing price of our common stock was $79.46 per share.

**Investing in our securities involves significant risks. We strongly recommend that you read carefully the risks we describe in this prospectus and in any accompanying prospectus supplement, as well as the risk factors that are incorporated by reference into this prospectus from our filings made with the Securities and Exchange Commission. See "[Risk Factors](#s3_07)" on page 5 of this prospectus.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.**

The date of this prospectus is December 4, 2025.

i

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| [PROSPECTUS](#s3_01) | i |
| [ABOUT THIS PROSPECTUS](#s3_03) | 1 |
| [ABOUT RADNET](#s3_04) | 2 |
| [WHERE YOU CAN FIND MORE INFORMATION](#s3_05) | 3 |
| [INFORMATION INCORPORATED BY REFERENCE](#s3_06) | 4 |
| [RISK FACTORS](#s3_07) | 5 |
| [CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS](#s3_08) | 6 |
| [USE OF PROCEEDS](#s3_09) | 7 |
| [DESCRIPTION OF COMMON STOCK](#s3_10) | 8 |
| [DESCRIPTION OF PREFERRED STOCK](#s3_11) | 12 |
| [DESCRIPTION OF DEBT SECURITIES](#s3_12) | 13 |
| [DESCRIPTION OF WARRANTS](#s3_13) | 22 |
| [DESCRIPTION OF SUBSCRIPTION RIGHTS](#s3_14) | 23 |
| [DESCRIPTION OF UNITS](#s3_15) | 24 |
| [LEGAL OWNERSHIP OF SECURITIES](#s3_16) | 25 |
| [SELLING STOCKHOLDERS](#s3_17) | 28 |
| [PLAN OF DISTRIBUTION](#s3_18) | 29 |
| [LEGAL MATTERS](#s3_19) | 33 |
| [EXPERTS](#s3_20) | 33 |
| [PART II](#s3_21) | II-1 |
| [INFORMATION NOT REQUIRED IN PROSPECTUS](#s3_22) | II-1 |
| [SIGNATURES](#s3_23) | II-7 |
| [POWER OF ATTORNEY](#s3_24) | II-7 |

---

ii

**ABOUT THIS PROSPECTUS**

This prospectus is part of an automatic "shelf" registration statement on Form S-3 that we filed with the Securities and Exchange Commission (the "SEC") using an automatic shelf registration process. Under this shelf registration process, we may offer and sell from time to time any combination of the securities described in this prospectus in one or more offerings in amounts, at prices and on terms that we determine at the time of the offering.

In addition, selling stockholders may use this prospectus to sell shares of our common stock from time to time. We will not receive any proceeds from the sale of the shares by selling stockholders. Selling stockholders may deliver a supplement with this prospectus, if required, to update the information contained in this prospectus. Selling stockholders may sell their shares of our common stock through any means described in the section entitled "Plan of Distribution" or described in any accompanying prospectus supplement. As used herein, the term "selling stockholders" includes the selling stockholders and any of their transferees, donees, pledgees or other successors

.

This prospectus only provides you with a general description of the securities we may offer. Each time we offer securities under this prospectus we will provide a prospectus supplement that describes the terms of the security being offered. The prospectus supplement also may add, update or change information contained in this prospectus. Before making an investment decision, you should read carefully both this prospectus and any prospectus supplement and any free writing prospectus prepared by or on behalf of us, together with the documents incorporated by reference into this prospectus as described below under the heading "Information Incorporated by Reference."

This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to the registration statement, including its exhibits. Those exhibits may be filed with the registration statement or may be incorporated by reference to earlier SEC filings listed in the registration statement or in subsequent filings that we may make under the Securities Exchange Act of 1934 (the "Exchange Act").

**We have not authorized anyone else to provide you with information that is different or in addition to that contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or any free writing prospectus prepared by us or on our behalf. We do not take any responsibility for, and can provide no assurance to the reliability of, any information that others may give. We are not making an offer to sell or soliciting an offer to buy our securities under any circumstance in any jurisdiction where the offer or solicitation is not permitted. You should assume that the information contained in this prospectus, any prospectus supplement or any free writing prospectus prepared by us or on our behalf is accurate only as of the date of the respective document in which the information appears, and that any information in documents that we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any prospectus supplement or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates.**

This prospectus and the information incorporated herein by reference may include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus are the property of their respective owners.

In this prospectus, unless otherwise indicated, "our company," "we," "us," "RadNet," or "our" refer to RadNet, Inc., a Delaware corporation, and its consolidated subsidiaries.

**ABOUT RADNET**

**Company Overview**

We are a national provider of diagnostic imaging services in the United States. As of September 30, 2025, we operated, directly or indirectly through joint ventures with hospitals, 407 centers located in Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. Our centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often reducing the cost and amount of care for patients. Internationally, our subsidiary The HLH Imaging Group Limited, provides teleradiology services for remote interpretation of images on behalf of providers within the framework of the United Kingdom's National Health Service.

In addition to our imaging business, we established a Digital Health business segment during our 2024 fiscal year, which combines our former Artificial Intelligence ("AI") business segment with our eRad, Inc. business. Our Digital Health segment develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology. The portfolio of software solutions is anchored by eRad, Inc.'s RIS/PACS, informatics designed specifically for outpatient radiology and DeepHealth OS, a cloud-native operating system that helps operate all aspects of the radiology service line from scheduling and patient preparation to technologist workflow to interpretation and referral management.

In addition, we are using AI to develop solutions that employ machine learning to assist radiologists and other clinicians in interpreting images and improving radiologist efficiency and patient care, initially in the fields of screening for breast, prostate, lung and colon cancers. Our DeepHealth, Inc. subsidiary has received clearance from the U.S. Food and Drug Administration ("FDA") for use of its SaigeQ "triage"/workflow products, the SaigeDX advanced diagnostic product and the Saige-Density breast density assessment software for screening breast mammography, which we have begun to roll out in certain markets as an Enhanced Breast Cancer Detection solution. Our Aidence Holding B.V. subsidiary is developing solutions for interpretation of chest and lung computed tomography scans for lung cancer screening. It has received the CE mark for its solution and has existing customers in seven European countries, with its largest concentration in the United Kingdom, and plans to submit an application for FDA clearance to sell in the United States. Our Quantib B.V. subsidiary is primarily focused on interpretation of prostate magnetic resonance imaging ("MRI") for widespread prostate cancer screening. Quantib's prostate MRI post-processing software has both FDA clearances and European CE marking. Our Digital Health segment provides these solutions to RadNet and to over 400 customers in the United States, Europe, and Israel.

**Principal Executive Office**

Our principal executive office is located at 1510 Cotner Avenue, Los Angeles, California 90025 and our telephone number at that address is (310) 478-7808. Our corporate website is *www.radnet.com*. Our filings with the SEC are posted on our website at *www.radnet.com*. Information contained on our website or that can be accessed through our website is not incorporated by reference in this prospectus and does not constitute a part of this prospectus.

**WHERE YOU CAN FIND MORE INFORMATION**

We file annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy and information statements, and amendments to reports filed or furnished pursuant to Sections 13(a), 14 and 15(d) of the Exchange Act. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding RadNet and other companies that file materials electronically with the SEC. Copies of our periodic and current reports and proxy statements may be obtained, free of charge, on our website at www.radnet.com under the "Investor Relations" tab. This reference to our Internet address is for informational purposes only and shall not, under any circumstances, be deemed to incorporate the information available at or through such Internet address into this prospectus.

**INFORMATION INCORPORATED BY REFERENCE**

The SEC allows us to "incorporate by reference" information into this prospectus from other documents that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference from documents we filed with the SEC prior to the date of this prospectus, while information incorporated by reference from documents we file with the SEC after the date of this prospectus will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the registration statement of which this prospectus is a part the information or documents listed below that we filed with the SEC (Commission File No. 001-33307):

&nbsp;&nbsp;&nbsp;&nbsp;· our [Annual Report on Form 10-K](https://www.sec.gov/Archives/edgar/data/790526/000162828025009481/rdnt-20241231.htm) for the fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025, as amended by Amendment No.
1 on [Form 10-K/A](http://www.sec.gov/Archives/edgar/data/790526/000168316825002860/radnet_10ka-2024.htm) , filed with the SEC
on April 28, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;· the Part III information contained in our definitive proxy statement on [Schedule 14A](http://www.sec.gov/Archives/edgar/data/790526/000162828025009481/rdnt-20241231.htm) for our 2025 annual meeting of stockholders, filed with the SEC on April 28, 2025, that was incorporated into our Annual Report
on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 3, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;· our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025 and September
30, 2025, filed with the SEC on [May 12, 2025](https://www.sec.gov/Archives/edgar/data/790526/000162828025024672/rdnt-20250331.htm) , [August 11, 2025](https://www.sec.gov/Archives/edgar/data/790526/000162828025039605/rdnt-20250630.htm) and [November 10, 2025](https://www.sec.gov/Archives/edgar/data/790526/000079052625000008/rdnt-20250930.htm) , respectively;

&nbsp;&nbsp;&nbsp;&nbsp;· our Current Reports on Form 8-K filed with the SEC on [June 12, 2025](https://www.sec.gov/Archives/edgar/data/790526/000168316825004440/radnet_8k.htm) and [October 21, 2025](https://www.sec.gov/Archives/edgar/data/790526/000168316825007694/radnet_8k.htm) (but excluding
the portions of such reports expressly noted as being furnished and not filed);

&nbsp;&nbsp;&nbsp;&nbsp;· the description of our common stock set forth in our registration statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/790526/000101968707000386/radnet_8a-021207.txt) , registering our common stock under the Exchange Act, filed with the SEC on February 13, 2007 (as amended on February 14, 2007),
pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

All documents that we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the completion of the sales of the securities offered hereby but excluding any information furnished to, rather than filed with, the SEC (unless expressly incorporated by reference herein), will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such documents.

You should rely only on the information contained or incorporated by reference in this prospectus, any accompanying prospectus supplement or any free writing prospectus filed by us with the SEC and any information about the terms of securities offered conveyed to you by us, our underwriters or agents. We have not authorized anyone else to provide you with additional or different information. These securities are only being offered in jurisdictions where the offer is permitted. You should not assume that the information contained in this prospectus, any accompanying prospectus supplement or any free writing prospectus is accurate as of any date other than their respective dates.

We will provide, without charge, to each person to whom a copy of this prospectus has been delivered, including any beneficial owner, on written or oral request, a copy of any or all of the documents incorporated by reference into this prospectus, except exhibits to such documents unless those exhibits are specifically incorporated by reference in such documents. Any such request should be directed to RadNet, Inc., 1510 Cotner Avenue Los Angeles, CA 90025, Attn: Legal Department, or you may call us at (310) 478-7808.

**RISK FACTORS**

An investment in any of the securities offered by this prospectus involves risk. The prospectus supplement applicable to each offering of our securities will contain a discussion of the risks applicable to the investment in the securities being offered in that offering. Before you make a decision to invest in our securities, in addition to all of the other information contained in or incorporated by reference into this prospectus and any prospectus supplement, you should carefully consider the risk factors incorporated by reference from our most recent annual report on Form 10-K, as updated by our subsequent filings under the Exchange Act, including Forms 10-Q and 8-K, and the risk factors contained in or incorporated by reference into any prospectus supplement.

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This prospectus and any prospectus supplement and the documents incorporated herein and therein by reference may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act.

Forward-looking statements reflect current views about future events and are based on our currently available financial, economic and competitive data and on current business plans. Actual events or results may differ materially depending on risks and uncertainties that may affect our operations, markets, services, prices and other factors.

In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," "assumption" or the negative of these terms or other comparable terminology. Forward-looking statements may include, among others, statements we make regarding:

&nbsp;&nbsp;&nbsp;&nbsp;· expectations concerning domestic and global economic conditions, rates of inflation, or changes in interest
rates;

&nbsp;&nbsp;&nbsp;&nbsp;· anticipated trends in our revenues, operating expenses or capital expenditures, and our financial guidance;

&nbsp;&nbsp;&nbsp;&nbsp;· expected timing and potential impact of regulatory changes affecting our business;

&nbsp;&nbsp;&nbsp;&nbsp;· expected future market acceptance for our products or services, and our competitive strengths in the market we serve;

&nbsp;&nbsp;&nbsp;&nbsp;· our ability to successfully acquire and integrate new businesses, and achieve expected benefits, synergies or operating results from
those acquisitions; and

&nbsp;&nbsp;&nbsp;&nbsp;· our ability to successfully acquire and integrate new imaging operations;

&nbsp;&nbsp;&nbsp;&nbsp;· cost savings, efficiencies and improvements anticipated from our investments in artificial intelligence
and machine learning products and services; and

&nbsp;&nbsp;&nbsp;&nbsp;· economics and cost savings anticipated to be derived from our investments in artificial intelligence and
machine learning products and solutions.

Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to known and unknown risks, uncertainties and other factors that are difficult to predict and out of our control. Our actual results, level of activity, performance or achievements may be materially different from any future results, levels of activity, performance or achievements expressed or implied by forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated or implied in our forward-looking statements include the factors included in "Risk Factors," in our annual report on Form 10-K for the fiscal year ended December 31, 2024, as updated by our subsequent filings under the Exchange Act, including Forms 10-Q and 8-K. You should consider the inherent limitations on, and risks associated with, forward-looking statements and not unduly rely on the accuracy of predictions contained in such forward-looking statements.

These forward-looking statements speak only as of the date when they are made. We assume no obligation to revise or update any forward-looking statements for any reason, except as required by law.

**USE OF PROCEEDS**

Except as described in any applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities offered under this prospectus for general corporate purposes, which may include working capital, capital expenditures, acquisitions and refinancing or repayment of indebtedness. Specific allocations of the proceeds for such purposes have not been made at this time.

When securities are offered, the prospectus supplement relating thereto will set forth our intended use of the net proceeds that we receive from the sale of such securities. Pending the application of the net proceeds, we may invest the proceeds in marketable securities and short-term investments.

We will not receive any proceeds from the sale of common stock by selling stockholders pursuant to this prospectus.

**DESCRIPTION OF COMMON STOCK**

We may issue, separately or together with, or upon conversion, exercise or exchange of other securities, shares of our common stock, as set forth in the applicable prospectus supplement. The following description of our common stock is subject to and qualified in its entirety by reference to our certificate of incorporation, as amended to date (our "certificate of incorporation"), and our amended and restated bylaws, as amended to date (our "bylaws"), each of which has been filed with the SEC and are incorporated herein by reference. We encourage you to read our certificate of incorporation, our bylaws and the applicable provisions of the Delaware General Corporation Law (the "DGCL") for additional information regarding our common stock.

**Authorized Capitalization**

We are authorized to issue 200,000,000 shares of common stock having a par value of $.0001 per share and 30,000,000 shares of preferred stock having a par value of $.0001 per share. As of December 3, 2025, we had 77,282,458 shares of common stock outstanding and no shares of preferred stock outstanding.

Our authorized shares of common stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange or automated quotation system on which our securities may be listed or traded. If the approval of our stockholders is not so required, our board of directors may determine not to seek stockholder approval.

**Dividends**

Subject to the preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of assets legally available at the times and in the amounts that our board of directors may from time to time declare.

**Voting Rights**

Each holder of our common stock is entitled to one vote per share on all matters submitted to a vote of stockholders, and may not cumulate votes for the election of directors.

**Preemptive Rights; Redemption or Sinking Fund**

Holders of common stock have no preemptive, conversion or subscription rights. There are no redemption or sinking fund provisions applicable to our common stock.

**Liquidation Rights**

If we liquidate, dissolve or wind up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any outstanding shares of our preferred stock.

**Listing; Transfer Agent and Registrar**

Our common stock is listed on The Nasdaq Global Market under the symbol "RDNT." The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC. Their address is 55 Challenger Road, Suite 200B 2nd floor, Ridgefield Park, NJ 07660 and their telephone number is (800) 937-5449.

**Anti-Takeover Effects of Provisions of the DGCL and Our Charter Documents**

The following provisions of the DGCL and our certificate of incorporation and bylaws may affect the control of our company.

Delaware General Corporation Law

Section 203 of the DGCL ("Section 203") generally prohibits any Delaware corporation from engaging in any "business combinations" with any "interested stockholder" for a period of three years following the date the stockholder became an interested stockholder, unless:

&nbsp;&nbsp;&nbsp;&nbsp;· prior to such time, the board of directors approved either the business combination or the transaction
that resulted in the stockholder becoming an interested stockholder;

&nbsp;&nbsp;&nbsp;&nbsp;· upon completion of the transaction that resulted in the stockholder becoming an interested stockholder,
the interested stockholder owned at least 85% of the corporation's voting stock outstanding at the time the transaction commenced,
excluding for purposes of calculating the total voting stock outstanding (but not the outstanding voting stock owned by the interested
stockholder) those shares held (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants
do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer;
or

&nbsp;&nbsp;&nbsp;&nbsp;· at or subsequent to such time, the business combination is approved by the board of directors and authorized
at an annual or special meeting of stockholders by the affirmative vote of holders of at least two-thirds of the outstanding voting stock
that is not owned by the interested stockholder.

Generally, a "business combination" includes a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. Section 203 defines a "business combination" to include:

&nbsp;&nbsp;&nbsp;&nbsp;· any merger or consolidation of the corporation or any of its direct or indirect majority-owned subsidiaries
with either the interested stockholder or any other person or entity if the transaction is caused by the interested stockholder;

&nbsp;&nbsp;&nbsp;&nbsp;· any sale, lease, exchange, mortgage, transfer, pledge or other disposition of the assets of the corporation
or any direct or indirect majority-owned subsidiary involving the interested stockholder if the value of the assets exceeds 10% or more
of the market value of the corporation's consolidated assets or outstanding stock;

&nbsp;&nbsp;&nbsp;&nbsp;· subject to specified exceptions, any transaction that results in the issuance or transfer by the corporation
or any of its direct or indirect majority-owned subsidiaries of any stock of the corporation or the subsidiary to the interested stockholder;

&nbsp;&nbsp;&nbsp;&nbsp;· Subject to specified exceptions, any transaction involving the corporation or any of its direct or indirect
majority-owned subsidiaries that has the effect of increasing the proportionate share of the stock of any class or series of the corporation
or the subsidiary beneficially owned by the interested stockholder; or

&nbsp;&nbsp;&nbsp;&nbsp;· any receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or
other financial benefits provided by or through the corporation or any of its direct or indirect majority-owned subsidiaries.

Subject to certain exceptions, an "interested stockholder" is any entity or person who, together with that person's or entity's affiliates and associates, owns, or within the previous three years did own, 15% or more of the outstanding voting stock of the corporation.

Under certain circumstances, Section 203 makes it more difficult for an interested stockholder to consummate business combinations with a corporation for a three-year period. The provisions of Section 203 may cause a depression in our stock price and may also delay, discourage or prohibit transactions not approved in advance by our board of directors, such as takeover attempts that might otherwise involve payment to our stockholders of a premium over the market price of our common stock. A person interested in acquiring our company may therefore be inclined to seek early approval from our board of directors of either the business combination or the transaction that results in such person becoming an interested stockholder in order to avoid the stockholder approval requirement.

Certificate of Incorporation and Bylaw Provisions.

Some provisions of our certificate of incorporation and bylaws may have an anti-takeover effect and may delay, defer or prevent a tender offer or takeover attempt that a stockholder might deem to be in its, his or her best interest. The existence of these provisions might reduce the price that investors would be willing to pay in the future for shares of our common stock or other securities. These provisions include:

&nbsp;&nbsp;&nbsp;&nbsp;· *Special Stockholder Meetings*. Only a majority of the members of our board
of directors, or a duly authorized committee thereof, may call a special meeting of stockholders; however, if and to the extent that any
special meeting of stockholders may be called by any other person or persons specified in any certificate of designations filed under
Section 151(g) of the DGCL, then such special meeting may also be called by the person or persons in the manner, at the times and for
the purposes so specified.

· *Advance Notification of Shareholder Nominations and Proposals*. Our bylaws
establish advance notice procedures with respect to shareholder proposals and the nomination of candidates for election as directors,
other than nominations made by or at the direction of the board of directors or a committee of the board of directors. The bylaws do not
give the board of directors the power to approve or disapprove shareholder nominations of candidates or proposals regarding business to
be conducted at a special or annual meeting of the shareholders. Our bylaws provide that shareholders seeking to nominate candidates for
election to the board of directors at an annual or special meeting of shareholders or seeking to bring business before an annual meeting
must provide timely notice of their proposal in writing to our corporate secretary. Generally, to be timely, a shareholder's notice
regarding an annual meeting of shareholders must be received at our principal executive offices not less than 120 days prior to the first
anniversary of the previous year's annual meeting of shareholders. Our bylaws also specify requirements as to the form and content
of a shareholder's notice, which may have the effect of precluding the conduct of certain business at a meeting if the proper procedures
are not followed. In addition, these provisions may impede shareholder's ability to bring matters before an annual meeting of shareholders
or to make nominations for directors. These provisions may also discourage or deter a potential acquiror from conducting a solicitation
of proxies to elect the acquiror's own slate of directors or otherwise attempting to obtain control of us.

· *Authorized but Unissued Shares*. Our board of directors could issue a series
of preferred stock that could, depending on the terms of such series, delay, defer, discourage or prevent an attempt to acquire our company
or an otherwise change in control of our company. Our board of directors may designate and issue authorized but unissued shares of preferred
stock (as well as issue shares of authorized but unissued common stock) without further action by stockholders, subject to certain limitations
imposed by the NASDAQ Stock Market. If the approval of stockholders is not required for the issuance of shares of our common stock or
preferred stock, our board of directors may determine to issue shares without seeking stockholders' approval. The issuance of shares
in connection with the implementation of a stockholder rights plan may be utilized in an effort to dilute the stock ownership and voting
power of persons seeking to obtain control of our company. Our board of directors may also issue shares to investors who would support
our board of directors in opposing an unsolicited takeover bid. Our board of directors would make any determination to issue such shares
based on its judgment as to the best interests of our company and our stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;· *Vacancies in our Board of Directors*. Our certificate of incorporation and
bylaws provide that vacancies shall be filled pursuant to a resolution adopted by a majority of the remaining members of our board of
directors then in office, although less than a quorum, or by a sole remaining director. In addition, whenever the holders of any class
or classes of stock or series thereof are entitled to elect one or more directors under the terms of our certificate of incorporation,
vacancies and newly created directorships of such class or classes or series may be filled by a majority of the directors elected by such
class or classes or series thereof then in office, or by a sole remaining director so elected. Each director shall hold office until his
or her successor is elected and qualified, unless the director dies, resigns or otherwise leaves the board of directors before then.

&nbsp;&nbsp;&nbsp;&nbsp;· *No Cumulative Voting*. The DGCL provides that stockholders of a Delaware
corporation are not entitled to the right to cumulate votes in the election of directors unless its certificate of incorporation provides
otherwise. Our certificate of incorporation does not permit stockholders to cumulate votes in the election of directors.

&nbsp;&nbsp;&nbsp;&nbsp;· *Transfer Restrictions*. Our certificate of incorporation contains provisions
generally restricting any direct or indirect transfer of shares of our capital stock where the transferee(s), individually or collectively,
is or would become a "5-percent shareholder," as such term is defined in the U.S. Internal Revenue Service Treasury Regulation
ss. 1.382-2T(g) (referred to herein as the Treasury Regulation), or would increase the ownership percentage of an existing 5-percent shareholder.
Such transfer restrictions are intended to preserve certain of our tax assets and any attempted transfer of our capital stock to a 5-percent
shareholder in violation of the provisions of our certificate of incorporation will be void ab initio. Under the Treasury Regulation,
5-percent shareholder generally means an individual or group that owns five percent or more of the applicable company, however, the Treasury
Regulation is complex and you are encouraged to consult with your tax advisors to determine whether or not you are a 5-percent shareholder
for purposes of the Treasury Regulation.

**Limitations on Liability and Indemnification Provisions**

Section 102(b)(7) of the DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors' fiduciary duties. Our certificate of incorporation contains a provision that eliminates the personal liability of a director to us or our stockholders for monetary damages for breach of fiduciary duty as a director to the fullest extent permitted by the DGCL.

Our certificate of incorporation and bylaws also include provisions that provide for indemnification of officers and directors to the fullest extent permitted by, and in the manner permissible under, applicable state and federal law, including the DGCL. We have also entered into separate indemnification agreements with our officers and directors, pursuant to which we agreed to indemnify the officer or director against all liabilities relating to his or her position as an officer or director of our company, or as an employee, agent, officer or director of any other entity if the officer or director is serving in that capacity at our request, to the fullest extent permitted under applicable law.

Our certificate of incorporation and bylaws also expressly authorize us to carry directors' and officers' insurance for the benefit of our directors, officers, employees and agents. We maintain policies insuring our officers and directors against certain civil liabilities, including liabilities under the Securities Act. The effect of this insurance is to indemnify any of our officers or directors against expenses, including attorneys' fees, judgments, fines and amounts paid in settlement, incurred by an officer or director upon a determination that such person acted in good faith. We pay the premiums for this insurance. We believe that these indemnification provisions and insurance are useful to attract and retain qualified directors and executive officers.

The limitation of liability and indemnification provisions in our certificate of incorporation and bylaws may discourage our stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, the stockholder's investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or controlling persons pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In addition, indemnification for violations of state securities laws may be limited by applicable laws.

**DESCRIPTION OF PREFERRED STOCK**

We may issue, separately or together with, or upon conversion, exercise or exchange of other securities, preferred stock as set forth in the applicable prospectus supplement. Subject to the limitations imposed by law and the rules of the NASDAQ Stock Market, our board of directors is authorized to designate and issue up to 30,000,000 shares of preferred stock in one or more series, without further stockholder approval.

Our board of directors is authorized from time to time to fix the designations and the powers, preferences and relative, participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including, without limitation, the dividend rate, conversion or exchange rights, redemption price and liquidation preference, of any series of shares of preferred stock, and to fix the number of shares constituting any such series, and to increase or decrease the number of shares of any such series (but not below the number of shares thereof then outstanding). Any or all of these rights may be superior to the rights of our common stock.

We will set forth in the applicable prospectus supplement a description of any series of preferred stock that may be offered pursuant to this prospectus, including:

&nbsp;&nbsp;&nbsp;&nbsp;· the designation and stated value of that series;

&nbsp;&nbsp;&nbsp;&nbsp;· the number of shares of preferred stock we are offering;

&nbsp;&nbsp;&nbsp;&nbsp;· the public offering price at which the shares of preferred stock will be sold;

&nbsp;&nbsp;&nbsp;&nbsp;· the dividend rate of that series, the conditions and dates upon which those dividends
will be payable, whether those dividends will be cumulative or noncumulative, and, if cumulative, the date from which dividends will accumulate;

&nbsp;&nbsp;&nbsp;&nbsp;· the process for any auction and remarketing, if any;

&nbsp;&nbsp;&nbsp;&nbsp;· the relative ranking and preferences of that series as to dividend rights and rights
upon any liquidation, dissolution or winding up of the affairs of our company;

&nbsp;&nbsp;&nbsp;&nbsp;· any redemption, repurchase, or sinking fund provisions;

&nbsp;&nbsp;&nbsp;&nbsp;· any conversion or exchange rights of the holder or us;

&nbsp;&nbsp;&nbsp;&nbsp;· any voting rights;

&nbsp;&nbsp;&nbsp;&nbsp;· any preemptive rights;

&nbsp;&nbsp;&nbsp;&nbsp;· any restrictions on transfer, sale or other assignment;

&nbsp;&nbsp;&nbsp;&nbsp;· any restrictions on further issuances;

&nbsp;&nbsp;&nbsp;&nbsp;· whether interests in the preferred stock will be represented by depositary shares;

&nbsp;&nbsp;&nbsp;&nbsp;· a discussion of any material United States federal income tax considerations applicable
to the preferred stock;

&nbsp;&nbsp;&nbsp;&nbsp;· any application for listing of that series on any securities exchange or market;

&nbsp;&nbsp;&nbsp;&nbsp;· any limitations on the issuance of any class or series of preferred stock ranking
senior to or on a parity with the series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding
up of our company's affairs; and

&nbsp;&nbsp;&nbsp;&nbsp;· any other specific terms, preferences, rights or limitations of, or restrictions
on, that series of preferred stock.

The issuance of preferred stock will affect, and may adversely affect, the rights of holders of our common stock.

It is not possible to state the actual effect of the issuance of any shares of preferred stock on the rights of holders of common stock until our board of directors determines the specific rights, preferences and privileges attached to that series of preferred stock. The effects of issuing preferred stock could include one or more of the following:

&nbsp;&nbsp;&nbsp;&nbsp;· restricting dividends on our common stock;

&nbsp;&nbsp;&nbsp;&nbsp;· diluting the voting power of holders of our common stock;

&nbsp;&nbsp;&nbsp;&nbsp;· impairing the liquidation rights of holders of our common stock; or

&nbsp;&nbsp;&nbsp;&nbsp;· delaying or preventing changes in control or management.

As of the date of this prospectus, no shares of preferred stock are outstanding and our board of directors has made no provision for this issuance of any series of preferred stock.

**DESCRIPTION OF DEBT SECURITIES**

We may issue senior debt securities or subordinated debt securities (any of which may be convertible or not convertible). We use the term "debt securities" in this prospectus to refer to both senior debt securities and subordinated debt securities. No debt securities will be secured by any of our property or assets or the property or assets of any of our subsidiaries. No debt securities will be guaranteed by any of our subsidiaries or any other person or entity. Thus, by owning a debt security, you will be an unsecured creditor of RadNet.

The senior debt securities will be issued under our senior debt indenture described below and will rank equally with all of our other unsecured and unsubordinated debt. The subordinated debt securities will be issued under our subordinated debt indenture described below and will be subordinate in right of payment to all of our "senior debt," as defined in the subordinated debt indenture. We use the term "indentures" in this prospectus to refer to both the senior debt indenture and the subordinated debt indenture. Neither indenture limits our ability to incur additional unsecured indebtedness, unless otherwise described in the prospectus supplement relating to any series of debt securities.

The following summary does not purport to be complete and is subject to, and is qualified in its entirety by reference to, all provisions of the indentures, including definitions of various terms contained in the indentures. Copies of the entire indentures are exhibits to the registration statement of which this prospectus is a part, and are incorporated herein by reference. We encourage you to read the full text of the indentures, which you can obtain links to under the "Exhibits" listed elsewhere in this prospectus. While the terms we have summarized below will apply generally to any future debt securities we may offer under this prospectus, the applicable prospectus supplement or free writing prospectus will describe the specific terms of any debt securities offered through that prospectus supplement or free writing prospectus. The terms of any debt securities we offer under a prospectus supplement or free writing prospectus may differ from the terms we describe below.

RadNet is a holding company and a legal entity separate and distinct from its subsidiaries through which RadNet conducts its operations and which generate all of RadNet's operating income and cash flow. As a result, RadNet's only source of funds to meet its obligations to make payments under any debt securities, as well as its other payment obligations, its distributions or advances from its subsidiaries. Contractual provisions, laws or regulations may limit the ability of RadNet to obtain the necessary funds from its subsidiaries to satisfy its payment obligations. RadNet's rights to participate in the distribution of assets of its subsidiaries are effectively subordinate to the claims of creditors, including trade creditors, of those subsidiaries, except to the extent that RadNet itself may be a creditor of a particular subsidiary with recognized claims. Accordingly, except to the extent that RadNet itself may be a creditor of a subsidiary with recognized claims, RadNet's obligations under its debt securities will be effectively subordinated to all existing and future indebtedness and liabilities of its subsidiaries.

**The Indentures**

The senior debt securities and the subordinated debt securities are each governed by an agreement called an indenture – the senior debt indenture, in the case of the senior debt securities, and the subordinated debt indenture, in the case of the subordinated debt securities. Each indenture is a contract between us and the trustee under the indenture. The indentures are substantially identical, except for the provisions relating to subordination, which are included only in the subordinated debt indenture.

At or prior to the time of offering of any series of debt securities, we will appoint a trustee under the applicable indenture. We will identify the trustee in the prospectus supplement offering any series of debt securities.

The trustee under each indenture has two principal roles:

&nbsp;&nbsp;&nbsp;&nbsp;· The trustee can enforce the rights of the holders against us if we default on our
obligations under the terms of the indenture or the debt securities. There are some limitations on the extent to which the trustee acts
on behalf of the holders, described below under the heading "Events of Default."

&nbsp;&nbsp;&nbsp;&nbsp;· The trustee performs administrative duties for us, such as sending interest payments
and notices to holders, and transferring a holder's debt securities to a new buyer if a holder sells.

Reference to the indenture or the trustee with respect to any debt securities, means the indenture under which those debt securities are issued and the trustee under that indenture.

**Conversion or Exchange Rights**

We will set forth in the applicable prospectus supplement or free writing prospectus the terms on which a series of debt securities may be convertible into or exchangeable for our common stock, our preferred stock or other securities (including securities of a third-party). We will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock, our preferred stock or other securities (including securities of a third-party) that the holders of the series of debt securities receive would be subject to adjustment.

**Terms**

We may issue as many distinct series of debt securities as we wish under either debt indenture. The provisions of each indenture allow us not only to issue debt securities with terms different from those previously issued under that indenture, but also to "reopen" a previous issue of a series of debt securities and issue additional debt securities of that series. We may issue debt securities in amounts that exceed the total amount specified on the cover of a prospectus supplement at any time without notification or consent.

This section summarizes the material terms of the debt securities that are common to all series, although the prospectus supplement which describes the terms of each series of debt securities may also describe differences from the material terms summarized here. This summary is subject to and qualified by reference to the description of the particular terms of any series described in the applicable prospectus supplement. Those terms may vary from the terms described in this prospectus. There may also be a further prospectus supplement, known as a pricing supplement or free writing prospectus, which contains the precise terms of debt securities you may be offered.

In this summary, we describe the meaning of only some of the more important terms. Whenever we refer to particular sections or defined terms of the indenture in this prospectus or in the prospectus supplement, such sections or defined terms are incorporated by reference here or in the prospectus supplement. You must look to the indenture for the most complete description of what we describe in summary form in this prospectus.

We may issue the debt securities as original issue discount securities, which will be offered and sold at a substantial discount below their stated principal amount. The prospectus supplement relating to the original issue discount securities will describe federal income tax consequences and other special considerations applicable to them. The debt securities may also be issued as indexed securities or securities denominated in foreign currencies or currency units, as described in more detail in the prospectus supplement relating to any of the particular debt securities.

The prospectus supplement relating to a series of debt securities will describe the terms of the series, including:

&nbsp;&nbsp;&nbsp;&nbsp;· the title of the series of debt securities;

&nbsp;&nbsp;&nbsp;&nbsp;· whether they are senior debt securities or subordinated debt securities;

&nbsp;&nbsp;&nbsp;&nbsp;· any limit on the aggregate principal amount of the series of debt securities;

&nbsp;&nbsp;&nbsp;&nbsp;· the person to whom interest on a debt security is payable, if other than the holder
on the regular date;

&nbsp;&nbsp;&nbsp;&nbsp;· the stated maturity;

&nbsp;&nbsp;&nbsp;&nbsp;· the specified currency, currencies or currency, units for principal and interest,
if not U.S. dollars;

&nbsp;&nbsp;&nbsp;&nbsp;· the rate or rates, which may be fixed or variable per annum, at which the series
of debt securities will bear interest, if any, and the date or dates from which that interest, if any, will accrue;

&nbsp;&nbsp;&nbsp;&nbsp;· the place or places where the principal of, premium, if any, and interest on the
debt securities will be payable;

&nbsp;&nbsp;&nbsp;&nbsp;· the denominations in which the debt securities will be issuable, if other than
denominations of $1,000 and any integral multiple of $1,000;

&nbsp;&nbsp;&nbsp;&nbsp;· any mandatory or optional sinking funds or similar provisions or provisions for
redemption at the option of the issuer;

&nbsp;&nbsp;&nbsp;&nbsp;· the date, if any, after which and the price or prices at which the series of debt
securities may, in accordance with any option or mandatory redemption provisions, be redeemed and the other detailed terms and provisions
of those optional or mandatory redemption provisions, if any;

&nbsp;&nbsp;&nbsp;&nbsp;· any index or formula used to determine the amount of payments of principal of and
any premium and interest on the debt securities;

&nbsp;&nbsp;&nbsp;&nbsp;· if the debt securities may be converted into or exchanged for our common stock,
preferred stock or other securities, the terms on which such conversion or exchange may occur, including whether conversion or exchange
is mandatory, at the option of the holder or at our option, the period during which conversion or exchange may occur, the initial conversion
or exchange rate and the circumstance or manner in which the amount of common or preferred stock issuable upon conversion or exchange
may be adjusted or calculated according to the market price of our common stock or preferred stock or such other securities;

&nbsp;&nbsp;&nbsp;&nbsp;· if the debt securities are original issue discount debt securities, the yield to
maturity;

&nbsp;&nbsp;&nbsp;&nbsp;· the applicability of any provisions described under the heading "Defeasance
and Covenant Defeasance" below;

&nbsp;&nbsp;&nbsp;&nbsp;· any event of default under the series of debt securities, if different from those
described under the heading "Event of Default" below;

&nbsp;&nbsp;&nbsp;&nbsp;· the names and duties of any co-trustees, authenticating agents, paying agents,
transfer agents or registrars for the debt securities;

&nbsp;&nbsp;&nbsp;&nbsp;· if the series of debt securities will be issuable only in the form of a global
security, the depositary or its nominee with respect to the series of debt securities and the circumstances under which the global security
may be registered for transfer or exchange in the name of a person other than the depository or the nominee;

&nbsp;&nbsp;&nbsp;&nbsp;· if the debt securities are guaranteed, the identity of the subsidiary guarantors
providing the guarantees and a description of the terms of the guarantees; and

&nbsp;&nbsp;&nbsp;&nbsp;· any other terms of the debt securities, which could be different from or in addition
to those described in this prospectus.

**Form, Exchange and Transfer**

Unless we indicate otherwise in the prospectus supplement, the debt securities will be issued (1) only in fully registered form and (2) in denominations of $1,000 and integral multiples of $1,000.

Holders may exchange their debt securities for debt securities of the same series in any authorized denominations, as long as the total principal amount is not changed.

Holders may exchange or transfer their debt securities at the office of the trustee. They may also replace lost, stolen or mutilated debt securities at that office. The trustee acts as our agent for registering debt securities in the names of the holders and transferring debt securities.

Holders will not be required to pay a service charge to transfer or exchange their debt securities, but they may be required to pay for any tax or other governmental charge associated with the registration, exchange or transfer. The transfer or exchange, and any replacement, will be made only if our transfer agent is satisfied with the holder's proof of legal ownership. The transfer agent may require an indemnity before replacing any debt securities.

If a debt security is issued as a global debt security, only the depositary will be entitled to transfer and exchange the debt security as described in this subsection, since the depositary will be the sole holder of the debt security.

If a debt security is issued as a registered global debt security, only the depositary – such as DTC, Euroclear and Clearstream, each as defined in the section "Legal Ownership of Securities" below – will be entitled to transfer and exchange the debt security as described in this subsection, since the depositary will be the sole holder of the debt security. Those who own beneficial interests in a global security do so through participants in the depositary's securities clearance system, and the rights of these indirect owners will be governed solely by the applicable procedures of the depositary and its participants. We describe book-entry procedures in the section "Legal Ownership of Securities" below.

We will not deposit money on a regular basis into any separate custodial account to repay the debt securities. In addition, we will not be entitled to redeem a debt security before its stated maturity unless the prospectus supplement specifies a redemption commencement date. You will not be entitled to require us to buy a debt security from you before its stated maturity unless your prospectus supplement specifies one or more repayment dates.

If the debt securities are redeemable and we redeem less than all of the debt securities of a particular series, we may block the transfer or exchange of debt securities during the period beginning 15 days before the day we mail the notice of redemption and ending on the day of that mailing, in order to freeze the list of holders to prepare the mailing. We may also refuse to register transfers or exchanges of debt securities selected for redemption, except that we will continue to permit transfers and exchanges of the unredeemed portion of any debt security being partially redeemed.

The rules for exchange described above apply to an exchange of debt securities for other debt securities of the same series and kind. If a debt security is convertible, or exchangeable into or for a different kind of security, the terms governing that type of conversion or exchange will be described in the prospectus supplement.

**Payment and Paying Agents**

If interest is due on a debt security on an interest payment date, we will pay the interest to the person in whose name the debt security is registered at the close of business on the regular record date relating to the interest payment date as will be specified in the applicable prospectus supplement. If interest is due at maturity but on a day that is not an interest payment date, we will pay the interest to the person entitled to receive the principal of the debt security. If principal or another amount besides interest is due on a debt security at the stated maturity, we will pay the amount to the holder of the debt security against surrender of the debt security at a proper place of payment or, in the case of a global debt security, in accordance with the applicable policies of the depositary.

We will make payments on a global security in accordance with the applicable policies of the depositary as in effect from time to time. Under those policies, we will make payments directly to the depositary, or its nominee, and not to any indirect owners who own beneficial interests in the global security.

Book-entry and other indirect holders should consult their banks, brokers or other financial institutions for information on how they will receive payments.

We will make payments on a debt security in non-global, registered form as follows. We will pay interest that is due on an interest payment date by check mailed on the interest payment date to the holder at his or her address shown on the trustee's records as of the close of business on the regular record date. We will make all other payments by check to the paying agent against surrender of the debt security.

All payments will be made in U.S. Dollars unless the prospectus supplement provides otherwise. If payments are to be made in currency other than U.S. Dollars, such payments for debt security in non-global, registered form will be made by wire transfer of immediately available funds to any account that is maintained in the applicable specified currency at a bank designated by the holder and which is acceptable to us and the trustee. To designate an account for wire payment, the holder must give the paying agent appropriate wire instructions at least five business days before the requested wire payment is due. If we are obligated to make a payment in a specified currency other than U.S. Dollars, and the specified currency or any successor currency is not available to us due to circumstances beyond our control, we will be entitled to satisfy our obligation to make the payment by making the payment in U.S. Dollars, on the basis of the exchange rate determined by the designated exchange agent, in its discretion.

We may appoint one or more financial institutions to act as our paying agents, at whose designated offices debt securities in non-global entry form may be surrendered for payment at their maturity. We call each of those offices a paying agent. We may add, replace or terminate paying agents from time to time. We may also choose to act as our own paying agent. Initially, the appointed trustee will act as the paying agent.

Regardless of who acts as paying agent, all money paid by us to a paying agent that remains unclaimed at the end of two years after the amount is due to a holder will be repaid to us. After that two-year period, the holder may look only to us for payment and not to the trustee, any other paying agent or anyone else.

**Notices**

Notices to be given to holders of a global debt security will be given only to the depositary, in accordance with its applicable policies as in effect from time to time. Notices to be given to holders of debt securities not in global form will be sent by mail to the respective addresses of the holders as they appear in the trustee's records. Neither the failure to give any notice to a particular holder, nor any defect in a notice given to a particular holder, will affect the sufficiency of any notice given to another holder.

**Mergers and Similar Transactions**

Under the terms of the applicable indenture, we will generally be permitted to merge or consolidate with another entity. We will also generally be permitted to sell our assets substantially as an entirety to another entity. With regard to any series of debt securities, however, unless otherwise indicated in the applicable prospectus supplement, we may not take any of these actions unless all of the following conditions are met:

&nbsp;&nbsp;&nbsp;&nbsp;· If we are not the successor entity in the transaction, the successor entity must
be a corporation, partnership, limited liability company or trust organized under the laws of the United States, any state in the United
States or the District of Columbia and must expressly assume our obligations under the debt securities of that series and the indenture
with respect to that series.

&nbsp;&nbsp;&nbsp;&nbsp;· Immediately after giving effect to the transaction, no default under the debt securities
of that series has occurred and is continuing. For this purpose, "default under the debt securities of that series" means
an event of default with respect to that series or any event that would be an event of default with respect to that series if the requirements
for giving us a default notice and for our default having to continue for a specific period of time were disregarded.

&nbsp;&nbsp;&nbsp;&nbsp;· We have delivered to the trustee an officers' certificate and opinion of
counsel, each stating that the transaction complies in all respects with the indenture.

If the conditions described above are satisfied with respect to the debt securities of any series, we will not need to obtain the approval of the holders of those debt securities in order to merge or consolidate or to sell our assets. Also, these conditions will apply only if we wish to merge or consolidate with another entity or sell our assets substantially as an entirety to another entity. We will not need to satisfy these conditions if we enter into other types of transactions, including any transaction in which we acquire stock or assets of another entity, any transaction that involves a change of control of us but in which we do not merge or consolidate and any transaction in which we sell less than substantially all of our assets.

**Defeasance and Covenant Defeasance**

Any series of issued debt securities may be subject to the defeasance and discharge provisions of the applicable indenture. Under those provisions, the debt securities of any series may authorize us to elect to:

&nbsp;&nbsp;&nbsp;&nbsp;· defease and to discharge us from any and all obligations with respect to those
debt securities, except for the rights of holders of those debt securities to receive payments on the securities solely from the trust
fund established pursuant to the applicable indenture and the obligations to exchange or register the transfer of the securities, to replace
temporary or mutilated, destroyed, lost or stolen securities, to maintain an office or agency with respect to the securities and to hold
moneys for payment in trust, which we refer to as a defeasance; or

&nbsp;&nbsp;&nbsp;&nbsp;· to be released from our obligations with respect to those debt securities to comply
with the restrictive covenants which are subject to covenant defeasance, and the occurrence of certain events of default with respect
to those restrictive covenants shall no longer be an event default, which we refer to as a covenant defeasance.

To invoke defeasance or covenant defeasance with respect to any series of debt securities, we must irrevocably deposit with a trustee, in trust, money or U.S. Government obligations, or both, which will provide money in an amount sufficient to pay all sums due on that series.

As a condition to defeasance or covenant defeasance, we must deliver to the applicable indenture trustee an officers' certificate and an opinion of counsel stating that holders of the applicable debt securities will not recognize gain or loss for federal income tax purposes as a result of the defeasance or covenant defeasance and will be subject to federal income tax on the same amounts, in the same manner and at the same times as would have been the case if we did not elect the defeasance or covenant defeasance. We may exercise our defeasance option with respect to the securities notwithstanding our prior exercise of our covenant defeasance option. If we exercise our defeasance option, payment of the securities may not be accelerated by the reference to restrictive covenants which are subject to covenant defeasance. If we do not comply with our remaining obligations after exercising our covenant defeasance option and the debt securities are declared due and payable because of the occurrence of any event of default, the amount of money and U.S. Government obligations on deposit in the defeasance trust may be insufficient to pay amounts due on the securities at the time of the acceleration. However, we will remain liable for those payments.

**Modification and Waiver of the Debt Securities**

We may change or modify either of the indentures without the consent of the holders of the debt securities so long as such changes are limited to clarifications and/or changes that would not adversely affect the debt securities of that series in any material respect. We may also make changes that may affect the debt securities that have yet to be issued under the applicable indentures without the approval of any holders.

If the proposed change shall affect the debt securities of a particular series then we must obtain approval of the holders of a majority in principal amount of the debt securities of that series. If the proposed change will affect the debt securities of more than one series of debt securities issued under the applicable indenture then we must obtain approval of the holders of a majority in principal amount of each series affected by the change.

We may not amend the subordinated debt indenture to alter the subordination of any outstanding subordinated debt securities without the written consent of each holder of senior debt then outstanding who would be adversely affected. In addition, we may not modify the subordination provisions of the subordinated debt indenture in a manner that would adversely affect the outstanding subordinated debt securities of any one or more series in any material respect, without the approval of the holders of a majority in aggregate principal amount of all affected series, voting together as one class.

In each case, the required approval must be given by written consent.

Book-entry and other indirect holders should consult their banks, brokers or other financial institutions for information on how approval may be granted or denied if we seek to change or modify either indenture or the debt securities or request a waiver.

**Subordination Provisions**

Holders of subordinated debt securities should recognize that contractual provisions in the subordinated debt indenture may prohibit us from making payments on those securities. Subordinated debt securities are subordinate and junior in right of payment, to the extent and in the manner stated in the subordinated debt indenture, to all of our senior debt, as defined in the subordinated debt indenture, as it may be supplemented from time to time, including all debt securities we have issued and will issue under the senior debt indenture.

The subordinated debt indenture defines "senior debt" as the principal of (and premium, if any) and interest (including interest accruing on or after the filing of any petition in bankruptcy or for reorganization relating to us) on all of our indebtedness (including indebtedness of others guaranteed by us), other than the subordinated debt securities, whether outstanding on the date of the indenture or thereafter created, incurred or assumed, which is (i) for money borrowed, (ii) evidenced by a note or similar instrument given in connection with the acquisition of any businesses, properties or assets of any kind or (iii) obligations of ours as lessee under leases required to be capitalized on the balance sheet of the lessee under generally accepted accounting principles or leases of property or assets made as part of any sale and lease-back transaction to which we are a party, including amendments, renewals, extensions, modifications and refundings of any such indebtedness or obligation, unless in any case in the instrument creating or evidencing any such indebtedness or obligation, or pursuant to which the same is outstanding, it is provided that such indebtedness or obligation is not superior in right of payment to the subordinated debt securities.

The subordinated debt indenture provides that, unless all principal of and any premium or interest on the senior debt has been paid in full, no payment or other distribution may be made in respect of any subordinated debt securities in the following circumstances:

&nbsp;&nbsp;&nbsp;&nbsp;· in the event of any insolvency or bankruptcy proceedings, or any receivership,
liquidation, reorganization or other similar proceeding involving us or our assets;

&nbsp;&nbsp;&nbsp;&nbsp;· (a) in the event and during the continuation of any default in the payment of principal, premium or interest
on any senior debt beyond any applicable grace period or if any event of default with respect to any senior debt of ours has occurred
and is continuing, permitting the holders of that senior debt of ours or a trustee to accelerate the maturity of that senior debt, unless
the event of default has been cured or waived or ceased to exist and any related acceleration has been rescinded, or (b) if any judicial
proceeding is pending with respect to a payment default or an event of default described in clause (a); or

&nbsp;&nbsp;&nbsp;&nbsp;· in the event that any subordinated debt securities have been declared due and payable
before their stated maturity.

If the trustee under the subordinated debt indenture or any holders of the subordinated debt securities receive any payment or distribution that they know is prohibited under the subordination provisions, then the trustee or the holders will have to repay that money to the holders of the senior debt.

Even if the subordination provisions prevent us from making any payment when due on the subordinated debt securities of any series, we will be in default on our obligations under that series if we do not make the payment when due. This means that the trustee under the subordinated debt indenture and the holders of that series can take action against us, but they will not receive any money until the claims of the holders of senior debt have been fully satisfied.

**Events of Default**

Unless the applicable prospectus supplement provides otherwise, when we refer to an event of default with respect to any series of debt securities, we mean any of the following:

&nbsp;&nbsp;&nbsp;&nbsp;· failure to pay interest on any debt security of that series within 30 days after
its due date;

&nbsp;&nbsp;&nbsp;&nbsp;· failure to pay the principal of or any premium on any debt security of that series
on the due date;

&nbsp;&nbsp;&nbsp;&nbsp;· failure to deposit a sinking fund payment with regard to any debt security of that
series on the due date, but only if the payment is required under the applicable prospectus supplement;

&nbsp;&nbsp;&nbsp;&nbsp;· we remain in breach of any covenant we make in the indenture for the benefit of the relevant series for
90 days after we receive a written notice of default stating that we are in breach and requiring us to remedy the breach. The notice must
be sent by the trustee or the holders of at least a majority in principal amount of the relevant series of debt securities; or

&nbsp;&nbsp;&nbsp;&nbsp;· the occurrence of specified bankruptcy, insolvency or reorganization events.

An event of default for one series of debt securities does not necessarily constitute an event of default for any other series. The trustee may withhold notice to the debt securities holders of any default, except a payment default, if it considers such action to be in the holders' interests.

If the specified bankruptcy, insolvency or reorganization events occur, the entire principal of all the debt securities of that series will be due and payable immediately. If any other event of default occurs and continues, the trustee, or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the series, may declare the entire principal of all the debt securities of that series to be due and payable immediately. If this happens, and the issuer cures the event of default in the manner specified in the applicable indenture, the holders of a majority of the aggregate outstanding principal amount of the debt securities of that series can void the acceleration of payment.

The indentures provide that the trustee has no obligation to exercise any of its rights at the direction of any holders, unless the holders offer the trustee reasonable indemnity. If they provide this indemnification, the holders of a majority in principal amount of any series of debt securities have the right to direct any proceeding, remedy, or power available to the trustee with respect to that series.

Book-entry and other indirect holders should consult their banks, brokers or other financial institutions for information on how to give notice or direction to or make a request of the trustee and to make or cancel a declaration of acceleration.

We will provide the trustee every year with a written statement of certain of our officers certifying that to their knowledge we are in compliance with the applicable indenture and the debt securities issued under it, or else specifying any default.

**The Trustee**

If we offer a series of debt securities, we will identify the banking or financial institution which will act as trustee under the applicable indenture in the prospectus supplement for that offering. If a single banking or financial institution acts as trustee with respect to both the indentures, and a default occurs with respect to any series of debt securities, the banking or financial institution would generally be required to resign as trustee under one of the indentures within 90 days of the default, unless the default were cured, duly waived or otherwise eliminated.

**Governing Law**

Unless otherwise specified in an applicable prospectus supplement, New York law will govern the indentures and the debt securities.

**DESCRIPTION OF WARRANTS**

We may issue warrants for the purchase of shares of common stock, preferred stock or debt securities in one or more series. We may issue warrants independently or together with shares of common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities.

We will set forth in the applicable prospectus supplement a description of any series of warrants that may be offered pursuant to this prospectus, including:

&nbsp;&nbsp;&nbsp;&nbsp;· the title of the warrants;

&nbsp;&nbsp;&nbsp;&nbsp;· the aggregate number of the warrants;

&nbsp;&nbsp;&nbsp;&nbsp;· the price or prices at which the warrants will be issued;

&nbsp;&nbsp;&nbsp;&nbsp;· in the case of warrants to purchase common stock or preferred stock, the number
of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which
these shares may be purchased upon such exercise;

&nbsp;&nbsp;&nbsp;&nbsp;· the designation, aggregate principal amount, denominations and terms of the debt
securities purchasable upon exercise of a warrant to purchase debt securities and the price at which the debt securities may be purchased
upon exercise;

&nbsp;&nbsp;&nbsp;&nbsp;· if applicable, the date on and after which the warrants and the related securities
will be separately transferable;

&nbsp;&nbsp;&nbsp;&nbsp;· the effect of any merger, consolidation, sale or other disposition of our business
on the warrant agreements and the warrants;

&nbsp;&nbsp;&nbsp;&nbsp;· the terms of any rights to redeem or call the warrants;

&nbsp;&nbsp;&nbsp;&nbsp;· any provisions for changes to or adjustments in the exercise price or number of
securities issuable upon exercise of the warrants;

&nbsp;&nbsp;&nbsp;&nbsp;· the date on which the right to exercise the warrants will commence and the date
on which the right will expire;

&nbsp;&nbsp;&nbsp;&nbsp;· if applicable, the minimum or maximum number of warrants that may be exercised
at any one time;

&nbsp;&nbsp;&nbsp;&nbsp;· the manner in which the warrant agreements and warrants may be modified;

&nbsp;&nbsp;&nbsp;&nbsp;· information relating to book-entry procedures, if any;

&nbsp;&nbsp;&nbsp;&nbsp;· if applicable, a discussion of material United States federal income tax considerations
of holding or exercising the warrants; and

&nbsp;&nbsp;&nbsp;&nbsp;· any other terms of the warrants, including terms, procedures and limitations relating
to the exchange and exercise of the warrants.

Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including:

&nbsp;&nbsp;&nbsp;&nbsp;· in the case of warrants to purchase debt securities, the right to receive payments
of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable
indenture; or

&nbsp;&nbsp;&nbsp;&nbsp;· in the case of warrants to purchase common stock or preferred stock, the right
(a) to receive dividends, if any, or payments upon our liquidation, dissolution or winding up, or (b) to exercise voting rights, if any.

We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant agreement, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering before the issuance of the related series of warrants. We urge you to read the applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the warrant agreements and warrant certificates that contain the terms of the warrants.

**DESCRIPTION OF SUBSCRIPTION RIGHTS**

We may issue subscription rights to purchase our securities. These subscription rights may be issued independently or together with any other security offered hereby and may or may not be transferable by the stockholder receiving the subscription rights in such offering.

We will set forth in the applicable prospectus supplement a description of any subscription rights that may be offered pursuant to this prospectus, including:

&nbsp;&nbsp;&nbsp;&nbsp;· whether common stock, preferred stock, or warrants for those securities will be
offered under the stockholder subscription rights;

&nbsp;&nbsp;&nbsp;&nbsp;· the price, if any, for the subscription rights;

&nbsp;&nbsp;&nbsp;&nbsp;· the exercise price payable for each security upon the exercise of the subscription
rights;

&nbsp;&nbsp;&nbsp;&nbsp;· the number of subscription rights issued to each stockholder;

&nbsp;&nbsp;&nbsp;&nbsp;· the number and terms of the securities which may be purchased per each subscription
right;

&nbsp;&nbsp;&nbsp;&nbsp;· the extent to which the subscription rights are transferable;

&nbsp;&nbsp;&nbsp;&nbsp;· any other terms of the subscription rights, including the terms, procedures and
limitations relating to the exchange and exercise of the subscription rights;

&nbsp;&nbsp;&nbsp;&nbsp;· the date on which the right to exercise the subscription rights shall commence,
and the date on which the subscription rights shall expire;

&nbsp;&nbsp;&nbsp;&nbsp;· the extent to which the subscription rights may include an over-subscription privilege
with respect to unsubscribed securities;

&nbsp;&nbsp;&nbsp;&nbsp;· if appropriate, a discussion of material U.S. federal income tax considerations;
and

&nbsp;&nbsp;&nbsp;&nbsp;· if applicable, the material terms of any standby underwriting or purchase arrangement
entered into by us in connection with the offering of subscription rights.

If the subscription rights are offered pursuant to a subscription rights certificate, we will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of subscription rights certificate that describes the terms of the particular subscription rights we are offering before the issuance of the subscription rights. We urge you to read the applicable prospectus supplements related to the particular subscription rights that we may offer under this prospectus, as well as any related free writing prospectuses, and the subscription rights certificate, if any.

**DESCRIPTION OF UNITS**

We may issue units comprised of one or more of the other securities described in this prospectus or any prospectus supplement in any combination. We will set forth in the applicable prospectus supplement a description of any units that may be offered pursuant to this prospectus. Unless otherwise stated in the applicable prospectus supplement, each unit will be issued so that the holder of the unit is also the holder, with the rights and obligations of a holder, of each security included in the unit. The units may be issued under unit agreements to be entered into between us and a unit agent, which may provide that the securities included in the unit may not be held or transferred separately, at any time or times before a specified date or upon the occurrence of a specified event or occurrence.

If units are offered pursuant to a unit agreement, we will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of unit agreement that describes the terms of the particular units we are offering before the issuance of the units. We urge you to read the applicable prospectus supplements related to the particular units that we may offer under this prospectus, as well as any related free writing prospectuses, the actual provisions of the unit and/or any unit agreement.

**LEGAL OWNERSHIP OF SECURITIES**

We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the "holders" of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names as "indirect holders" of those securities. As we discuss below, indirect holders are not legal holders and investors in securities issued in book-entry form or in street name will be indirect holders.

**Legal Holders**

Our obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form.

For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we would seek approval only from the holders, and not the indirect holders, of the securities. Whether and how the holders contact the indirect holders is up to the holders.

**Special Considerations For Indirect Holders**

If you hold securities through a bank, broker or other financial institution, either in book-entry form or in street name, you should check with your own institution to find out:

&nbsp;&nbsp;&nbsp;&nbsp;· how it handles securities payment and notices;

&nbsp;&nbsp;&nbsp;&nbsp;· whether it imposes fees or charges;

&nbsp;&nbsp;&nbsp;&nbsp;· how it would handle a request for the holders' consents, if ever required;

&nbsp;&nbsp;&nbsp;&nbsp;· whether and how you can instruct it to send your securities registered in your
own name so you can be a registered holder;

&nbsp;&nbsp;&nbsp;&nbsp;· how it would exercise rights under the securities if there were a default or other
event triggering the need for holders to act to protect their interests; and

&nbsp;&nbsp;&nbsp;&nbsp;· if the securities are in book-entry form, how the depositary's rules and
procedures will affect these matters.

**Book-Entry Holders**

We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary's book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.

Only the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form will be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities.

As a result, investors in a book-entry security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary's book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not holders, of the securities.

**Street Name Holders**

We may terminate a global security or issue securities in non-global form. In these cases, investors may choose to hold their securities in their own names or in "street name." Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution.

For securities held in street name, we will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities.

**Global Securities**

A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms.

Each security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all securities issued in book-entry form.

A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under "Special Situations When a Global Security Will Be Terminated." As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a holder of the security, but only an indirect holder of a beneficial interest in the global security.

If the prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.

**Special Considerations For Global Securities**

As an indirect holder, an investor's rights relating to a global security will be governed by the account rules of the investor's financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.

If securities are issued only in the form of a global security, an investor should be aware of the following:

&nbsp;&nbsp;&nbsp;&nbsp;· an investor cannot cause the securities to be registered in his or her name, and
cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below;

&nbsp;&nbsp;&nbsp;&nbsp;· an investor will be an indirect holder and must look to his or her own bank or
broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above;

&nbsp;&nbsp;&nbsp;&nbsp;· an investor may not be able to sell interests in the securities to some insurance
companies and to other institutions that are required by law to own their securities in non-book-entry form;

&nbsp;&nbsp;&nbsp;&nbsp;· an investor may not be able to pledge his or her interest in a global security
in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in
order for the pledge to be effective;

&nbsp;&nbsp;&nbsp;&nbsp;· the depositary's policies, which may change from time to time, will govern
payments, transfers, exchanges and other matters relating to an investor's interest in a global security. We and any applicable
trustee have no responsibility for any aspect of the depositary's actions or for its records of ownership interests in a global
security. We and the trustee also do not supervise the depositary in any way;

&nbsp;&nbsp;&nbsp;&nbsp;· the depositary may, and we understand that DTC will, require that those who purchase
and sell interests in a global security within its book-entry system use immediately available funds, and your broker or bank may require
you to do so as well; and

&nbsp;&nbsp;&nbsp;&nbsp;· financial institutions that participate in the depositary's book-entry system,
and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices and
other matters relating to the securities.

There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries.

**Special Situations When A Global Security Will Be Terminated**

In a few special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above.

A global security will terminate when the following special situations occur:

&nbsp;&nbsp;&nbsp;&nbsp;· if the depositary notifies us that it is unwilling, unable or no longer qualified
to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days;

· if we notify any applicable trustee that we wish to terminate that global security;
or

&nbsp;&nbsp;&nbsp;&nbsp;· if an event of default has occurred with regard to securities represented by that
global security and has not been cured or waived.

The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.

**SELLING STOCKHOLDERS**

This prospectus also relates to the possible resale or other disposition by certain stockholders who acquired shares of our common stock directly from us. Such stockholders are referred to as "selling stockholders" in this prospectus. Information about selling security holders, if any, will be set forth in the applicable prospectus supplement, in a post-effective amendment, or in other filings we make with the SEC which are incorporated by reference.

**PLAN OF DISTRIBUTION**

We or selling stockholders may sell the securities offered under this prospectus from time to time in any one or more of the following ways:

&nbsp;&nbsp;&nbsp;&nbsp;· to or through underwriters, brokers or dealers (acting as agent or principal);

&nbsp;&nbsp;&nbsp;&nbsp;· directly to one or more other purchasers;

&nbsp;&nbsp;&nbsp;&nbsp;· upon the exercise of rights distributed or issued to our security holders;

&nbsp;&nbsp;&nbsp;&nbsp;· through a block trade in which the broker or dealer engaged to handle the block
trade will attempt to sell the securities as agent, but may position and resell a portion of the block as principal to facilitate the
transaction;

&nbsp;&nbsp;&nbsp;&nbsp;· in "at the market" offerings within the meanings of Rule 415(a)(4)
under the Securities Act or through a market maker or into an existing market, on an exchange, or otherwise;

&nbsp;&nbsp;&nbsp;&nbsp;· directly to purchasers, through a specific bidding or auction process, on a negotiated
basis or otherwise;

&nbsp;&nbsp;&nbsp;&nbsp;· through agents on a best-efforts basis;

&nbsp;&nbsp;&nbsp;&nbsp;· through any other method permitted pursuant to applicable law; or

&nbsp;&nbsp;&nbsp;&nbsp;· otherwise through a combination of any of the above methods of sale.

Sales of securities may be effected from time to time in one or more transactions, including negotiated transactions:

&nbsp;&nbsp;&nbsp;&nbsp;· at a fixed price or prices, which may be changed;

&nbsp;&nbsp;&nbsp;&nbsp;· at market prices prevailing at the time of sale;

&nbsp;&nbsp;&nbsp;&nbsp;· at prices related to prevailing market prices; or

&nbsp;&nbsp;&nbsp;&nbsp;· at negotiated prices.

Any selling stockholder will act independently of us in making decisions with respect to the timing, manner and size of each sale of shares of common stock covered by this prospectus.

Each time that we or selling stockholders sell securities pursuant to this prospectus, we will provide a prospectus supplement or supplements that will describe the method of distribution and set forth the terms and conditions of the offering of such securities, including the following information:

&nbsp;&nbsp;&nbsp;&nbsp;· the terms of the offering;

&nbsp;&nbsp;&nbsp;&nbsp;· the names of any underwriters, dealers or agents;

&nbsp;&nbsp;&nbsp;&nbsp;· the name or names of any managing underwriter or underwriters;

&nbsp;&nbsp;&nbsp;&nbsp;· the purchase price of the securities;

&nbsp;&nbsp;&nbsp;&nbsp;· the net proceeds to us, if any, from the sale of the securities;

&nbsp;&nbsp;&nbsp;&nbsp;· any underwriting discounts, concessions, commissions or agency fees and other items
constituting underwriters', dealers' or agents' compensation;

&nbsp;&nbsp;&nbsp;&nbsp;· any delayed delivery arrangements; and

&nbsp;&nbsp;&nbsp;&nbsp;· estimated offering expenses.

We may engage in at-the-market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. Any at-the market offering will be through an underwriter or underwriters acting as principal or agent for us.

We may issue to our existing security holders, through a dividend or similar distribution, subscription rights to purchase shares of our common stock or preferred stock, which may or may not be transferable. In any distribution of subscription rights to our existing security holders, if all of the underlying securities are not subscribed for, we may then sell the unsubscribed securities directly to third parties or may engage the services of one or more underwriters, dealers or agents, including standby underwriters, to sell the unsubscribed securities to third parties. The applicable prospectus supplement will describe the specific terms of any offering of our common stock or preferred stock through the issuance of subscription rights, including, if applicable, the material terms of any standby underwriting or purchase arrangement. The anticipated date of delivery of the securities offered by this prospectus will be described in the applicable prospectus supplement relating to the offering.

**Sale Through Underwriters or Dealers.**

The securities may be offered to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more of such firms. Unless otherwise set forth in the prospectus supplement, the obligations of underwriters or dealers to purchase the securities offered will be subject to certain conditions precedent and the underwriters or dealers will be obligated to purchase all the offered securities if any are purchased. Any public offering price and any discount or concession allowed or reallowed or paid by underwriters or dealers to other dealers may be changed from time to time.

Selling stockholders and broker-dealers or agents involved in an arrangement to sell any of the offered securities may, under certain circumstances, be deemed to be "underwriters" within the meaning of the Securities Act. Any profit on such sales and any discount, commission, concession or other compensation received by any such underwriter, broker-dealer or agent may be deemed an underwriting discount and commission under the Exchange Act. No selling stockholder has informed us that they have an agreement or understanding, directly or indirectly, with any person to distribute the common stock covered by this prospectus. If a selling stockholder should notify us that they have a material arrangement with a broker-dealer for the resale of their shares, we may be required to amend the registration statement of which this prospectus is a part, and file a prospectus supplement to describe the agreement between the selling stockholder and broker-dealer or agent, provide required information regarding the plan of distribution, and otherwise revise the disclosure in this prospectus as needed. We also may be required to file the agreement between the selling stockholder and the broker-dealer as an exhibit to the registration statement. Except as indicated in the applicable prospectus supplement, the selling stockholder and/or purchasers will pay all discounts, concessions, commissions and similar selling expenses, if any, that can be attributed to the sale of the shares of such common stock.

We or selling stockholders may grant to the underwriters options to purchase additional securities at the public offering price, with additional underwriting commissions or discounts, as applicable, set forth in the prospectus supplement. The terms of any option to purchase additional securities will be set forth in the prospectus supplement for those securities.

**Direct Sales and Sales through Agents**

We or selling stockholders may sell the securities offered through this prospectus directly. In this case, no underwriters, dealers or agents would be involved. Such securities may also be sold through agents designated from time to time. The prospectus supplement will name any agent involved in the offer or sale of the offered securities and will describe any commissions payable to the agent. Unless otherwise indicated in the prospectus supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment.

We or selling stockholders may sell the securities directly to institutional investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect to any sale of those securities. The terms of any such sales will be described in the prospectus supplement relating to the offer.

**Delayed Delivery Contracts**

If indicated in the applicable prospectus supplement, we may authorize underwriters, dealers or agents to solicit offers by certain institutional investors to purchase securities at the public offering price under delayed delivery contracts. These contracts would provide for payment and delivery on a specified date in the future. The contracts would be subject only to those conditions described in the prospectus supplement. The applicable prospectus supplement will describe the commission payable for solicitation of those contracts.

**Market Making, Stabilization and Other Transactions**

All securities we may offer pursuant to this prospectus, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities.

Any underwriter may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time.

Any underwriters or agents that are qualified market makers may engage in passive market making transactions in the common stock in accordance with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of our common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker's bid, however, the passive market maker's bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.

**Derivative Transactions and Hedging**

We or selling stockholders may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. The applicable prospectus supplement may indicate that, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or selling stockholders, or borrowed from us, selling stockholders, or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us or selling stockholders in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be identified in the applicable prospectus supplement (or a post-effective amendment). In addition, we or selling stockholders may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus. Such financial institution or other third party may transfer its economic short position to investors in our securities, or the securities of such selling stockholders, as applicable, or in connection with a concurrent offering of other securities.

We or selling stockholders may enter into option, share lending or other types of transactions that require us or selling stockholders, as applicable, to deliver shares of common stock to an underwriter, broker or dealer, who will then resell or transfer the shares of common stock under this prospectus. We or selling stockholders may also enter into hedging transactions with respect to our securities. For example, we may enter into option or other types of transactions that require us to deliver shares of common stock to an underwriter, broker or dealer, who will then resell or transfer the shares of common stock under this prospectus; or loan or pledge the shares of common stock to an underwriter, broker or dealer, who may sell the loaned shares or, in the event of default, sell the pledged shares.

**Electronic Auctions**

We may also make sales through the Internet or through other electronic means. Since we may from time to time elect to offer securities directly to the public, with or without the involvement of agents, underwriters or dealers, utilizing the Internet or other forms of electronic bidding or ordering systems for the pricing and allocation of such securities, you will want to pay particular attention to the description of that system, which we will provide in a prospectus supplement.

Such electronic system may allow bidders to directly participate, through electronic access to an auction site, by submitting conditional offers to buy that are subject to acceptance by us, and which may directly affect the price or other terms and conditions at which such securities are sold. These bidding or ordering systems may present to each bidder, on a so-called "real-time" basis, relevant information to assist in making a bid, such as the clearing spread at which the offering would be sold, based on the bids submitted, and whether a bidder's individual bids would be accepted, prorated or rejected. For example, in the case of debt security, the clearing spread could be indicated as a number of "basis points" above an index treasury note.

Upon completion of such an electronic auction process, securities will be allocated based on prices bid, terms of bid or other factors. The final offering price at which securities would be sold and the allocation of securities among bidders would be based in whole or in part on the results of the Internet or other electronic bidding process or auction.

**General Information**

Any securities initially sold outside the U.S. may be resold in the U.S. through underwriters, dealers or otherwise.

To comply with the securities laws of some states, if applicable, the securities that may be offered pursuant to this prospectus may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the securities may not be sold unless they have been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.

**LEGAL MATTERS**

Certain legal matters with respect to the primary offering contemplated hereby have been passed upon for us by Reed Smith LLP, Dallas, Texas. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.

**EXPERTS**

The consolidated financial statements of RadNet, Inc. and subsidiaries appearing in RadNet, Inc.'s Annual Report (Form 10-K) for the year ended December 31, 2024, and the effectiveness of RadNet, Inc. and subsidiaries' internal control over financial reporting as of December 31, 2024, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their reports thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing.

**PART II**

**INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 14. Other Expenses of Issuance and Distribution.**

The following table sets forth the estimated fees and expenses, other than underwriting discounts and commissions, expected to be incurred in connection with the offering or offerings described in this registration statement.

---

| | |
|:---|:---|
| **Item** | **Amount** |
| Securities and Exchange Commission registration fee<sup>(1)</sup> | $\*\* |
| FINRA filing fee | \*\* |
| Trustee fees and expenses | \*\* |
| Rating agency fees | \*\* |
| Legal fees and expenses | \*\* |
| Accounting fees and expenses | \*\* |
| Transfer agent and registrar fees and expenses | \*\* |
| Printing and EDGAR filing fees and expenses | \*\* |
| Miscellaneous expenses | \*\* |
| Total | $\*\* |

---

_______________________

(1) In accordance with Rules 456(b) and 457(r) under the Securities Act, the registrant is deferring payment of the registration fee associated with this registration statement.

\*\* These fees are variable based on the securities offered and accordingly cannot be estimated at this time. The applicable prospectus supplement will set forth the estimated amount of expenses incurred in connection with securities to be offered and sold pursuant to such prospectus supplement.

**Item 15. Indemnification of Directors and Officers.**

Set forth below is a description of certain provisions of the certificate of incorporation and amended and restated bylaws of RadNet, Inc. (the "registrant"), in each case, as amended to date (the "certificate of incorporation" and "bylaws," respectively), and the General Corporation Law of the State of Delaware ("DGCL") that relate to the indemnification of the directors and officers of the registrant. This description is intended only as a summary and is qualified in its entirety by reference to the certificate of incorporation, the bylaws and the DGCL.

**Delaware General Corporation Law**

Section 145 of the DGCL permits a corporation to indemnify directors and officers as well as other employees and individuals against expenses, including attorneys' fees, judgments, fines and amounts paid in settlement in connection with specified actions, suits and proceedings whether civil, criminal, administrative, or investigative, other than a derivative action by or in the right of the corporation, if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful. A similar standard applies to derivative actions (i.e., one brought by or on behalf of the corporation), except that indemnification extends only to expenses, including attorneys' fees, actually and reasonably incurred in connection with the defense or settlement of such action and no indemnification shall be provided if the indemnitee is adjudged to be liable to the corporation. The statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The court in which the action or suit was brought must determine that the indemnitee is fairly and reasonably entitled to indemnity for his or her expenses despite the adjudication of liability. The statute further provides that it is not exclusive of other indemnification that may be granted by a corporation's certificate of incorporation, bylaws, disinterested director vote, stockholder vote, agreement, or otherwise.

Section 145(g) of the DGCL also provides that a corporation may maintain insurance against liabilities even if the corporation would lack the power under the DGCL to indemnify against those liabilities.

**Certificate of Incorporation**

Article Ninth of the certificate of incorporation provides that directors will not be personally liable to the registrant or its stockholders for monetary damages for breach of fiduciary duty as a director to the fullest extent permitted by the DGCL. It further obligates the registrant, with respect to its officers and directors, and permits the registrant, with respect to its employee and agents, to indemnify, in the manner and to the fullest extent permitted by the DGCL, any person (or the estate of any person) who is or was a party to, or is threatened to be made a party to, any threatened, pending or completed action, suit or proceeding, whether or not by or in the right of the registrant, and whether civil, criminal, administrative, investigative or otherwise, by reason of the fact that the person is or was a director or officer, or employee or agent, as the case may be, of the registrant, or is or was serving at the request of the registrant as a director or officer, or employee or agent, as the case may be, of another corporation or entity.

The registrant may advance the expenses incurred by any such director, officer, employee or agent in defending any such action, suit or proceeding prior to its final disposition upon receipt of an undertaking by the recipient to repay the amounts advanced if it is ultimately determined that he or she is not entitled to be indemnified as authorized by the DGCL and the registrant's certificate of incorporation. To the fullest extent permitted by the DGCL, the indemnification provided in the certificate of incorporation includes expenses (including attorneys' fees), judgments, fines and amounts paid in settlement and, in the manner provided by the DGCL, the registrant may pay any of these expenses in advance of the final disposition of such action, suit or proceeding.

**Bylaws**

Article VII of the bylaws provides that the registrant shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the registrant) by reason of the fact that he is or was a director, officer, employee, or agent of the registrant, or is or was serving at the request of the registrant as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interest of the registrant. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interest of the registrant. Notwithstanding the foregoing, except with respect to a proceeding to enforce rights to indemnification or advancement of expenses under Article VII, the registrant is required to indemnify a person under this Article VII in connection with a proceeding (or part thereof) initiated by such person only if such proceeding (or part thereof) was authorized by the board of directors of the registrant.

The bylaws also obligate the registrant to advance expenses to its officers and directors, and require an undertaking to repay expenses under the specified conditions if required by applicable law. The registrant will indemnify each of its officers, directors, employees and agents in any action, suit or proceeding referred to in the above paragraph to the extent that person has been successful on the merits in defense thereof, or in defense of any claim, issue or matter therein, against expenses (including attorneys' fees) actually and reasonably incurred by that person in connection therewith; provided, however, that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the registrant unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. The payment of expenses incurred by an indemnitee in advance of the final disposition of the proceeding shall be made only upon receipt of an undertaking by the indemnitee to repay all amounts advanced if it should be ultimately determined that by final judicial decision from which there is no further right of appeal the indemnitee is not entitled to be indemnified under Article VII of the bylaws or applicable law.

The rights conferred on any person by Article VII of the bylaws are not exclusive of any other rights which such person may have or hereafter acquire under any statute, provision of the certificate of incorporation or bylaws, agreement, vote of stockholders or disinterested directors or otherwise.

Article VII of the bylaws further provides that the registrant may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the registrant.

**General**

The registrant has purchased and maintains directors' and officers' liability insurance covering many of the possible actions and omissions of persons acting or failing to act in such capacities, including liabilities arising under the Securities Act.

In addition to the above described provisions in the certificate of incorporation or bylaws, the registrant has entered into separate indemnification agreements with each of its officers and directors, which indemnify the officer or director against all liabilities relating to any action or inaction by such person in his or her capacity as an officer or director of the registrant, or as an employee, agent, officer or director of any other entity if the officer or director is serving in that capacity at the registrant's request, to the fullest extent permitted under applicable law and in furtherance of the provisions of Article VII.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to the registrant's directors, officers or controlling persons pursuant to the foregoing provisions, the registrant has been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In addition, indemnification for violations of state securities laws may be limited by applicable laws.

**Item 16. Exhibits.**

Set forth below is a list of exhibits filed as part of this Registration Statement:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 1.1 | Form of Underwriting Agreement with respect to Equity of RadNet, Inc.† |
| 1.2 | Form of Underwriting Agreement with respect to Debt Securities of RadNet, Inc.† |
| 3.1 | [Certificate of Incorporation of RadNet, Inc. dated June 19, 2008](https://www.sec.gov/Archives/edgar/data/790526/000101968708004043/radnet_8k-ex301.htm), incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K of RadNet, Inc. filed on September 4, 2008 |
| 3.2 | [Certificate of Amendment to Certificate of Incorporation of RadNet, Inc. dated September 2, 2008](https://www.sec.gov/Archives/edgar/data/790526/000101968708004043/radnet_8k-ex302.htm), incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K of RadNet, Inc. filed on September 4, 2008 |
| 3.3 | [Amended and Restated Bylaws of RadNet, Inc., as amended February 5, 2020](https://www.sec.gov/Archives/edgar/data/790526/000168316820000383/radnet_8k.htm), incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K of RadNet, Inc. filed on February 6, 2020 |
| 4.1 | [Form of Common Stock Certificate dated February 7, 2007](https://www.sec.gov/Archives/edgar/data/790526/000101968707000320/radnet_10k-ex0401.txt), incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-3 of RadNet, Inc. filed on December 26, 2019 |
| 4.2 | [Description of Securities dated February 12, 2007](https://www.sec.gov/Archives/edgar/data/790526/000101968707000386/radnet_8a-021207.txt), incorporated by reference to the Description of Common Stock in the Registration Statement on Form S-3 of RadNet, Inc. filed on December 26, 2019 |
| 4.3 | [Form of Senior Debt Indenture](https://www.sec.gov/Archives/edgar/data/790526/000161577414000542/s100586_ex4-2.htm), incorporated herein by reference to Exhibit 4.2 to the Registration Statement on Form S-3 of RadNet, Inc. filed on December 30, 2014 |
| 4.4 | [Form of Subordinated Debt Indenture](https://www.sec.gov/Archives/edgar/data/790526/000161577414000542/s100586_ex4-4.htm), incorporated herein by reference to Exhibit 4.4 to the Registration Statement on Form S-3 of RadNet, Inc. filed on December 30, 2014 |
| 4.5 | [Form of Senior Debt Security](https://www.sec.gov/Archives/edgar/data/790526/000161577414000542/s100586_ex4-2.htm), included in Exhibit 4.2 to the Registration Statement on Form S-3 of RadNet, Inc. filed on December 30, 2014 |
| 4.6 | [Form of Subordinated Debt Security](https://www.sec.gov/Archives/edgar/data/790526/000161577414000542/s100586_ex4-4.htm), included in Exhibit 4.4 to the Registration Statement on Form S-3 of RadNet, Inc. filed on December 30, 2014 |
| 4.7 | Form of Capital Stock Warrant Agreement (together with form of Capital Stock Warrant Certificate)† |
| 4.8 | Form of Debt Securities Warrant Agreement (together with form of Debt Securities Warrant Certificate)† |
| 4.9 | Form of Subscription Rights Agreement (together with form of Subscription Right Certificate)† |
| 4.10 | Form of Unit Agreement (together with form of Unit Certificate)† |
| 5.1 | [Legal Opinion of Reed Smith LLP](radnet_ex0501.htm)\* |
| 23.1 | [Consent of Independent Registered Public Accounting Firm](radnet_ex2301.htm)\* |
| 23.2 | Consent of Reed Smith LLP (included in [Exhibit 5.1](radnet_ex0501.htm))\* |
| 24.1 | [Power of Attorney](#s3_24) (included in the Signature Pages to this Registration Statement)\* |
| 25.1 | Form T-1 Statement of Eligibility under the Trust Indenture Act of 1939, as amended, of Trustee under the Senior Indenture (to be filed with the Securities and Exchange Commission within two business days following the offering or sale of the debt securities represented thereby) |
| 25.2 | Form T-1 Statement of Eligibility under the Trust Indenture Act of 1939, as amended, of Trustee under the Subordinated Indenture (to be filed with the Securities and Exchange Commission within two business days following the offering or sale of the debt securities represented thereby) |
| 107 | [Filing Fee Table](radnet_ex107.htm)\* |

---

___________________________

\* Filed herewith. <br> † To be filed as an exhibit to a Current Report on Form 8-K and incorporated by reference herein in connection with an offering of securities or by post-effective amendment to the Registration Statement.

**Item 17. Undertakings.**

(a) The undersigned registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change
in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b)
if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth
in the "Calculation of Registration Fee" table in the effective registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed
in the registration statement or any material change to such information in the registration statement;

*provided*, *however*, that paragraphs (a)(l)(i), (a)(l)(ii) and (a)(l)(iii) of this section do not apply if the registration statement is on Form S-3 and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the U.S. Securities and Exchange Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration
statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing
the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration
statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of
sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any
person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating
to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall
be deemed to be the initial *bona fide* offering thereof; *provided, however*, that no statement made in a registration statement
or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the
registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale
prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part
of the registration statement or made in any such document immediately prior to such effective date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required
to be filed pursuant to Rule 424;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant
or used or referred to by the undersigned registrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The portion of any other free writing prospectus relating to the offering containing material information
about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

(d) The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the Trustee to act under subsection (a) of Section 310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Securities and Exchange Commission under Section 305(b)(2) of the Trust Indenture Act.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California, on December 4, 2025.

---

| | |
|:---|:---|
| **RADNET, INC. a Delaware corporation** | **RADNET, INC. a Delaware corporation** |
| By: | /s/ Howard G. Berger, M.D. |
|  | **Howard G. Berger, M.D.** |
|  | President, Chief Executive Officer and Director<br> (Principal Executive Officer) |

---

**POWER OF ATTORNEY**

Each of the directors and/or officers of RadNet, Inc. whose signature appears below hereby appoints Howard G. Berger, M.D. and Mark D. Stolper, and each of them acting individually, as his or her true and lawful attorney-in-fact and agent, each with full power of substitution, to date and file with the Securities and Exchange Commission this registration statement on Form S-3, and to sign, date, and file any and all amendments to such registration statement, including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought, with all exhibits thereto and other documents in connection therewith, in each case on his or her behalf, in any and all capacities stated below, as appropriate, in such forms as they or any one of them may approve, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to act alone and to do and perform each and every act and thing requisite and necessary to be done to the end that such registration statement shall comply with the Securities Act of 1933, as amended, and the applicable rules and regulations adopted or issued pursuant thereto, as fully and to all intents and purposes as he or she might or could do in person, and generally to do all such things on their behalf in their capacities as officers and directors to enable the Registrant to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in their capacities and on the dates indicated below.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Howard G. Berger, M.D. | Director, Chief Executive Officer and President | December 4, 2025 |
| Howard G. Berger, M.D. | *(Principal Executive Officer)* |  |
| /s/ Mark D. Stolper | Chief Financial Officer | December 4, 2025 |
| Mark D. Stolper | *(Principal Financial Officer and Accounting Officer)* |  |
| /s/ Laura P. Jacobs | Director | December 4, 2025 |
| Laura P. Jacobs |  |  |
| /s/ Lawrence L. Levitt | Director | December 4, 2025 |
| Lawrence L. Levitt |  |  |
| /s/ Gregory E. Spurlock | Director | December 4, 2025 |
| Gregory E. Spurlock |  |  |
| /s/ David L. Swartz | Director | December 4, 2025 |
| David L. Swartz |  |  |
| /s/ Alma Gregory Sorensen | Director | December 4, 2025 |
| Alma Gregory Sorensen |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](image_001.jpg) | Reed Smith LLP<br> 2850 N Harwood Street<br> Suite 1500<br> Dallas, TX 75201<br> Tel +1 469 680 4200<br> Fax +1 469 680 4299<br> reedsmith.com |

---

December 4, 2025

RadNet, Inc.<br> 1510 Cotner Avenue

Los Angeles, California 90025

Ladies and Gentlemen:

This opinion is furnished to you in connection with a shelf Registration Statement on Form S-3 (the "<u>Registration Statement</u>") filed by RadNet, Inc., a Delaware corporation (the "<u>Company</u>"), with the Securities and Exchange Commission (the "<u>Commission</u>") on the date hereof in connection with the registration under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), for the offer and sale by the Company and the selling securityholders of the Company from time to time on a delayed or continuous basis pursuant to Rule 415 of the Securities Act of (i) shares of the Company's common stock, par value $0.0001 per share (the "<u>Common Stock</u>"), (ii) shares of the Company's preferred stock, par value $0.0001 per share (the "<u>Preferred Stock</u>"), which may be issued in one or more series, (iii) (A)senior debt securities, in one or more series (the "<u>Senior Debt Securities</u>"), which may be issued pursuant to an indenture to be dated on or about the date of the first issuance of Senior Debt Securities thereunder, by and between the Company and a trustee to be selected by the Company, in the form attached as Exhibit 4.3 to the Registration Statement (the "<u>Senior Indenture</u>"), and (B) subordinated debt securities, in one or more series (the "<u>Subordinated Debt Securities</u>" and, together with the Senior Debt Securities, the "<u>Debt Securities</u>"), which may be issued pursuant to an indenture to be dated on or about the date of the first issuance of Subordinated Debt Securities thereunder, by and between the Company and a trustee to be selected by the Company, in the form attached as Exhibit 4.4 to the Registration Statement (the "<u>Subordinated Indenture</u>"), (iv) warrants for the purchase of Common Stock, Preferred Stock or Debt Securities, in one or more series (the "<u>Warrants</u>"), which may be issued under warrant agreements, to be dated on or about the date of the first issuance of the applicable Warrants thereunder, by and between the Company and a warrant agent to be selected by the Company (each, a "<u>Warrant Agreement</u>"), (v) subscription rights to purchase the securities of the Company (the "<u>Rights</u>"), which may be issued pursuant to a rights agreement and certificates issued thereunder, to be dated on or about the date of the first issuance of the applicable Rights thereunder, by and between the Company and a rights agent to be selected by the Company (each, a "<u>Rights Agreement</u>"), and (vi) units comprised of one or more securities described in clauses (a)(i) through (v) above in any combination (the "<u>Units</u>" and, together with the Common Stock, the Preferred Stock, the Debt Securities, the Warrants and the Rights, collectively being referred to herein as the " <u>Securities</u>"), which may be issued under unit agreements, to be dated on or about the date of first issuance of the applicable Units thereunder, by and between the Company and a unit agent selected by the Company (each, a "<u>Unit Agreement</u>").

We are acting as counsel for the Company in connection with the registration of the Securities by the Company. This opinion is being furnished in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act.

In rendering the opinion set forth herein, we have examined originals or copies, certified or otherwise identified to our satisfaction, of such documents, corporate records, certificates of public officials and other instruments as we have deemed necessary or advisable.

**ABU DHABI ¨ ASTANA ¨ ATHENS ¨ AUSTIN ¨ BEIJING ¨ BRUSSELS ¨ CENTURY CITY ¨ CHICAGO ¨ DALLAS ¨ DUBAI ¨ FRANKFURT ¨ HONG KONG<br> HOUSTON ¨ LONDON ¨ LOS ANGELES ¨ MIAMI ¨ MUNICH ¨ NEW YORK ¨ ORANGE COUNTY ¨ PARIS ¨ PHILADELPHIA ¨ PITTSBURGH<br> PRINCETON ¨ RICHMOND ¨ SAN FRANCISCO ¨ SHANGHAI ¨ SILICON VALLEY ¨ SINGAPORE ¨ TYSONS ¨ WASHINGTON, D.C. ¨ WILMINGTON**

---

| | |
|:---|:---|
| RadNet, Inc.<br> December 4, 2025<br> Page 2 | ![](image_002.jpg) |

---

In such examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all items submitted to us as originals, the conformity with originals of all items submitted to us as copies, and the authenticity of the originals of such copies. As to any facts material to the opinions expressed herein that we did not independently establish or verify, we have relied upon statements and representations of officers and other representatives of the Company and public officials.

We have assumed that the Senior Indenture and the Subordinated Indenture will be duly authorized, executed, and delivered by the respective trustees thereunder and that the Warrant Agreement, Rights Agreement and Unit Agreement will each be duly authorized, executed, and delivered by the warrant agent, rights agent and unit agent, respectively, thereunder. With respect to our opinion as to the Common Stock and Securities convertible into or exercisable for shares of Common Stock, we have assumed that, at the time of issuance and sale, a sufficient number of shares of Common Stock are authorized and available for issuance under the Company's certificate of incorporation as then in effect and that the consideration for the issuance and sale of the Common Stock (or Warrants, Rights or options exercisable for, or Preferred Stock convertible into, Common Stock) is in an amount that is not less than the par value of the Common Stock. With respect to our opinion as to the Preferred Stock and the Securities convertible into or exercisable for shares of Preferred Stock, we have assumed that, at the time of issuance and sale, a sufficient number of shares of Preferred Stock are authorized and available for issuance under the Company's certificate of incorporation as then in effect and that the consideration for the issuance and sale of the Preferred Stock (or Warrants or Rights exercisable for Preferred Stock) is in an amount that is not less than the par value of the Preferred Stock. We have also assumed that any Warrants, Rights or Units offered under the Registration Statement, and the related Warrant Agreement, Rights Agreement and Unit Agreement, as applicable, will be executed in the forms to be filed as exhibits to the Registration Statement or incorporated by reference therein. We have not independently verified any of the foregoing assumptions.

This opinion is based solely on the General Corporation Law of the State of Delaware now in effect and, as to the Warrants, the Debt Securities, the Rights, and the Units constituting valid and binding obligations of the Company, insofar as such securities are governed by New York law, the existing internal laws of the State of New York now in effect. Without limiting the generality of the foregoing, we express no opinion with respect to (i) the qualification of the Securities under the securities or blue sky laws of any state or any foreign jurisdiction or (ii) the compliance with any federal or state law, rule or regulation relating to securities, or to the sale or issuance thereof.

Based upon and subject to the foregoing, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. With respect to the Common Stock, when (i) specifically authorized for issuance by the Company's board of directors or an authorized committee thereof (the "<u>Authorizing Resolutions</u>"), (ii) the Registration Statement, as finally amended (including all post-effective amendments), has become effective under the Securities Act, (iii) an appropriate prospectus supplement with respect to the Common Stock has been prepared, delivered and filed in compliance with the Securities Act and the applicable rules and regulations thereunder, (iv) if the Common Stock is to be sold pursuant to a purchase, underwriting or similar agreement (an "<u>Underwriting Agreement</u>"), such Underwriting Agreement with respect to the Common Stock in the form filed as an exhibit to the Registration Statement, any post-effective amendment thereto, or to a Current Report on Form 8-K, has been duly authorized, executed and delivered by the Company and the other parties thereto, (v) the terms of the sale of the Common Stock have been duly established in conformity with the Company's certificate of incorporation and bylaws, as then in effect, and do not violate any applicable law or result in a default under or breach of any agreement or instrument binding on the Company and comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company, (vi) the Common Stock has been issued and sold as contemplated by the Registration Statement and the prospectus included therein, and (vii) the Company has received the consideration provided for in the Authorizing Resolutions and, if applicable, the Underwriting Agreement, the Common Stock will be validly issued, fully paid and nonassessable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. With respect to the Preferred Stock, when (i) specifically authorized for issuance by the Authorizing Resolutions, (ii) the Registration Statement, as finally amended (including all post-effective amendments), has become effective under the Securities Act, (iii) an appropriate prospectus supplement with respect to the Preferred Stock has been prepared, delivered and filed in compliance with the Securities Act and the applicable rules and regulations thereunder, (iv) if the applicable shares of Preferred Stock are to be sold pursuant to an Underwriting Agreement, such Underwriting Agreement with respect to the applicable shares of Preferred Stock in the form filed as an exhibit to the Registration Statement, any post-effective amendment thereto, or to a Current Report on Form 8-K, has been duly authorized, executed and delivered by the Company and the other parties thereto, (v) an appropriate certificate or certificates of amendment or designation relating to a class or series of Preferred Stock to be sold under the Registration Statement has been duly authorized, adopted and filed with the Secretary of State of the State of Delaware prior to the issuance of the Preferred Stock, (vi) the terms of the sale of such class or series of Preferred Stock have been duly established in conformity with the Company's certificate of incorporation and bylaws, as then in effect, and do not violate any applicable law or result in a default under or breach of any agreement or instrument binding on the Company and comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company, (vii) shares of such class or series of Preferred Stock have been issued and sold as contemplated by the Registration Statement and the prospectus included therein, and (viii) the Company has received the consideration provided for in the Authorizing Resolutions and, if applicable, the Underwriting Agreement, the Preferred Stock will be validly issued, fully paid and nonassessable.

---

| | |
|:---|:---|
| RadNet, Inc.<br> December 4, 2025<br> Page 3 | ![](image_002.jpg) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. With respect to the Warrants, when (i) specifically authorized for issuance by the Authorizing Resolutions, (ii) the Registration Statement, as finally amended (including all post-effective amendments), has become effective under the Securities Act, (iii) the Warrant Agreement relating to the Warrants has been duly authorized, executed, and delivered by the Company, (iv) an appropriate prospectus supplement with respect to the applicable Warrants has been prepared, delivered and filed in compliance with the Securities Act and the applicable rules and regulations thereunder, (v) if the applicable Warrants are to be sold pursuant to an Underwriting Agreement, such Underwriting Agreement with respect to the applicable Warrants in the form filed as an exhibit to the Registration Statement, any post-effective amendment thereto or to a Current Report on Form 8-K, has been duly authorized, executed and delivered by the Company and the other parties thereto, (vi) the terms of the Warrants and of their issuance and sale have been duly established in conformity with the Warrant Agreement and do not violate any applicable law or result in a default under or breach of any agreement or instrument binding upon the Company and comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company, (vii) the Warrants have been duly executed and countersigned in accordance with the Warrant Agreement and issued and sold as contemplated by the Registration Statement and the prospectus included therein, and (viii) the Company has received the consideration provided for in the Authorizing Resolutions and, if applicable, the Underwriting Agreement, the Warrants will constitute valid and legally binding obligations of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. With respect to the Debt Securities, when (i) specifically authorized for issuance by the Authorizing Resolutions, (ii) the Senior Indenture or the Subordinated Indenture, whichever the case may be, has been duly authorized, executed, and delivered by the Company, (iii) the terms of the Debt Securities and of their issuance and sale have been duly established in conformity with the Senior Indenture or the Subordinated Indenture, whichever the case may be, and such terms, execution, issuance and sale as well as authentication of the Debt Securities do not violate any applicable law or result in a default under or breach of any agreement or instrument binding upon the Company and comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company, and (iv) such Debt Securities have been duly executed and authenticated in accordance with the Senior Indenture or the Subordinated Indenture, whichever the case may be, and issued and sold as contemplated in the Registration Statement and the prospectus included therein and any appropriate prospectus supplement, the Debt Securities will constitute valid and binding obligations of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. With respect to the Rights, when (i) specifically authorized for issuance by the Authorizing Resolutions, (ii) the Registration Statement, as finally amended (including all post-effective amendments), has become effective under the Securities Act, (iii) the Rights Agreement and any certificates relating to the Rights have been duly authorized, executed, and delivered by the Company, (iv) an appropriate prospectus supplement with respect to the applicable Rights has been prepared, delivered and filed in compliance with the Securities Act and the applicable rules and regulations thereunder, (v) if the applicable Rights are to be sold pursuant to an Underwriting Agreement, such Underwriting Agreement with respect to the applicable Rights in the form filed as an exhibit to the Registration Statement, any post-effective amendment thereto or to a Current Report on Form 8-K, has been duly authorized, executed and delivered by the Company and the other parties thereto, (vi) the terms of the Rights and of their issuance and sale have been duly established in conformity with the Rights Agreement and do not violate any applicable law or result in a default under or breach of any agreement or instrument binding upon the Company and comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company, (vii) the Rights have been duly executed and countersigned in accordance with the Rights Agreement and issued and sold as contemplated by the Registration Statement and the prospectus included therein, and (viii) the Company has received the consideration provided for in the Authorizing Resolutions and, if applicable, the Underwriting Agreement, the Rights will constitute valid and legally binding obligations of the Company.

---

| | |
|:---|:---|
| RadNet, Inc.<br> December 4, 2025<br> Page 4 | ![](image_002.jpg) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. With respect to the Units, when (i) specifically authorized for issuance by the Authorizing Resolutions, (ii) the Registration Statement, as finally amended (including all post-effective amendments), has become effective under the Securities Act, (iii) the Unit Agreement relating to the Units has been duly authorized, executed, and delivered by the Company, (iv) an appropriate prospectus supplement with respect to the applicable Units has been prepared, delivered and filed in compliance with the Securities Act and the applicable rules and regulations thereunder, (v) if the applicable Units are to be sold pursuant to an Underwriting Agreement, such Underwriting Agreement with respect to the applicable Units in the form filed as an exhibit to the Registration Statement, any post-effective amendment thereto or to a Current Report on Form 8-K, has been duly authorized, executed and delivered by the Company and the other parties thereto, (vi) the terms of the Units and of their issuance and sale have been duly established in conformity with the Unit Agreement and do not violate any applicable law or result in a default under or breach of any agreement or instrument binding upon the Company and comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company, (vii) the Units have been duly executed and countersigned in accordance with the Unit Agreement and issued and sold as contemplated by the Registration Statement and the prospectus included therein, and (viii) the Company has received the consideration provided for in the Authorizing Resolutions and, if applicable, the Underwriting Agreement, the Units will constitute valid and legally binding obligations of the Company.

We consent to the inclusion of this opinion as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act and further consent to all references to us under the caption "Legal Matters" in the Registration Statement. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the applicable rules and regulations of the Commission promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ REED SMITH LLP |
| REED SMITH LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the reference to our firm under the caption "Experts" in the Registration Statement (Form S-3) and related Prospectus of RadNet, Inc. for the registration of common stock, preferred stock, debt securities, warrants, subscription rights and units and to the incorporation by reference therein of our reports dated March 3, 2025, with respect to the consolidated financial statements of RadNet, Inc. and subsidiaries, and the effectiveness of internal control over financial reporting of RadNet, Inc. and subsidiaries, included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Los Angeles, California

December 4, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-3**

**RadNet, Inc.**

**Table 1: Newly Registered and Carry Forward Securities**

---

| | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Line Item Type** | **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> or Carry Forward Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** | **Carry Forward Form Type** | **Carry Forward File Number** | **Carry Forward Initial Effective Date** | **Filing Fee Previously Paid in Connection with<br>Unsold Securities<br>to be<br>Carried Forward** |
| *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* | *Newly Registered Securities* |
| Fees to be Paid | Equity | Common Stock, par value $0.0001 per share | (1) | 457(r) |  | $| $— | 0.0001381 | $— |  |  |  | $— |
| Fees to be Paid | Equity | Preferred Stock, par value $0.0001 per share | (2) | 457(r) |  |  |  | 0.0001381 |  |  |  |  |  |
| Fees to be Paid | Debt | Debt Securities | (3) | 457(r) |  |  |  | 0.0001381 |  |  |  |  |  |
| Fees to be Paid | Other | Warrants | (4) | 457(r) |  |  |  | 0.0001381 |  |  |  |  |  |
| Fees to be Paid | Equity | Subscription Rights | (5) | 457(r) |  |  |  | 0.0001381 |  |  |  |  |  |
| Fees to be Paid | Other | Units | (6) | 457(r) |  |  |  | 0.0001381 |  |  |  |  |  |
| Fees to be Paid | Equity | Secondary Offering: Common Stock, par value $0.0001 per share | (7) | 457(r) |  |  |  | 0.0001381 |  |  |  |  |  |
| *Carry Forward Securities* | *Carry Forward Securities* | *Carry Forward Securities* | *Carry Forward Securities* | *Carry Forward Securities* | *Carry Forward Securities* | *Carry Forward Securities* | *Carry Forward Securities* | *Carry Forward Securities* | *Carry Forward Securities* | *Carry Forward Securities* | *Carry Forward Securities* | *Carry Forward Securities* | *Carry Forward Securities* |
| Carry Forward Securities | Equity | Common stock, par value $0.0001 per share | (8) | 415(a)(6) | 45894 | $| $3328691.82 |  | $— | S-3 | 333-269025 | 12/27/2022 | $459.69 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $3328691.82 |  | 0.00 |  |  |  |  |
| Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: |  |  |  |  |  |  |  |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |  |  |  |  |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $0.00 |  |  |  |  |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) The registrant is relying on Rules 456(b) and 457(r) under the Securities Act of 1933, as amended (the "Securities Act"), to defer payment of all of the registration fee (except with respect to the carry forward securities identified in the table above, which registration fees have already been paid). In connection with the securities offered hereby, the registrant will pay "pay-as-you-go registration fees" in accordance with Rule 456(b) under the Securities Act. The registrant will calculate the registration fee applicable to an offer of securities pursuant to this Registration Statement based on the fee rate in effect on the date of such fee payment.

&nbsp;&nbsp;&nbsp;&nbsp;(2) See Offering Note 1.

&nbsp;&nbsp;&nbsp;&nbsp;(3) See Offering Note 1.

&nbsp;&nbsp;&nbsp;&nbsp;(4) See Offering Note 1.

&nbsp;&nbsp;&nbsp;&nbsp;(5) See Offering Note 1.

&nbsp;&nbsp;&nbsp;&nbsp;(6) See Offering Note 1.

&nbsp;&nbsp;&nbsp;&nbsp;(7) See Offering Note 1.

&nbsp;&nbsp;&nbsp;&nbsp;(8) The registrant has previously registered the resale of 59,444 shares of common stock of the registrant, par value $0.0001 per share (the "Common Stock"), by certain selling stockholders, offered by means of a 424(b)(7) prospectus supplement, dated October 21, 2025, to the prospectus dated December 27, 2022 (the "Resale Prospectus Supplement"), pursuant to a Registration Statement on Form S-3 (File No. 333-269025), filed with the Securities and Exchange Commission on December 27, 2022 (the "Prior Registration Statement"). In connection with the filing of the Resale Prospectus Supplement, the registrant made a contemporaneous fee payment in the amount of $595.41. A remaining of 45,894 shares of Common Stock registered for resale under the Resale Prospectus Supplement remained unsold (the "Unsold Shares"). Pursuant to Rule 415(a)(6) under the Securities Act, the aggregate registration fee of $459.69 that has already been paid and remains unused with respect to the Unsold Shares pursuant to the Resale Prospectus Supplement may be applied to the filing fees payable pursuant to this registration statement.